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ABSTRACT
Strong experimental and clinical evidence indicates that the urokinase type
plasminogen activation system is associated with many types of human cancer
invasion and metastasis. A component of this system, which is over-expressed on
cancer cell surfaces, urokinase plasminogen activator (uPA) is a potential marker that
may be targeted for anticancer therapy. The naturally occurring inhibitor, plasminogen
activator inhibitor type 2 (PAI-2), binds specifically to activated cell surface bound
uPA. Thus, the overall aim of this project was to assess the viability of using human
recombinant PAI-2 as a potential targeting device in future anti-cancer therapy
projects.

The dual colour flow cytometric analyses of breast and prostate cancer cell lines
confirmed that metastatic HS-578-T, MDA-MB-231 and PCS cell lines expressed
much higher levels of cell surface bound uPA than that of the non-metastatic MCF-7
cell line. Assessment of cell surface endogenous PAI-2 expression showed a small
difference between metastatic HS-578-T, MDA-MB-231 (higher) and non-metastatic
MCF-7 cells (lower). Assessment of exogenous FITC conjugated PAI-2 on HS-578-T
and MDA-MB-231 cells showed specific binding to cell surface bound uPA.

Assessment of cell surface uPA and GFP expression on MDA-MB-231+GFP cells by
flow cytometry showed that this transfected cell line maintained high uPA expression
levels in addition to high GFP expression without further Geneticin selection.
Examination by confocal microscopy visually confirmed that exogenous PAI-2 was
internalized into MDA-MB-231-f-GFP cells presumably via uPA binding and
endocytosis. This cell line will be used on murine breast cancer models as an easily

detectable tissue in histological examinations in the future studies.

An early stage breast cancer animal model was successfully obtained by subcutaneous
inoculation of MDA-MB-231 cells into mammary fat pads of nude mice.

In conclusion, the results of this project indicated the potential value of using human
recombinant PAI-2 and the MDA-MB-231 cell lines for future targeted anti-cancer
therapy projects.
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1. INTRODUCTION

1.1 AN OVERVIEW OF HUMAN CANCER INVASION AND METASTASIS

1.1.1 Biological features of human cancer

Carcinogenesis and metastasis are two key biological features of human cancer.
Carcinogenesis refers to the process whereby normal cells are transformed so that
they acquire the ability to grow without control and finally form the neoplasm or
primary tumour. Whether these tumours are malignant or benign depends upon the
ability of tumour cells to invade and spread (i.e. metastasize) throughout the body or
not, respectively (Franks, 1997).

Once the carcinogenic cellular phenotype has occurred and a neoplasm has formed,
the process of tumour invasion and metastasis (i.e. malignancy) continues to take
place under the influence of a variety of progression factors. These factors include:
proteases such as urokinase plasminogen activator (uPA) (Andreasen et al., 1997) and
cathepsin (Montcourrier, 1990), various angiogenic factors (Andreasen et al., 1997)
such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF)
and tissue factor (TF), and growth factors (Dickson et al., 1992) such as epidermal
growth factor (EGF) and transforming growth factor (TGF).

The process of human cancer metastasis can be summarized by five successive steps:
invasion, angiogenesis, intravasation,

extravasation

and metastasis formation

(Fig. 1.1). During tumour growth, cancer cells invade local normal surrounding

tissues. To grow beyond 1-2 mm in diameters, the neoplasm itself is invaded by
'normal' vascular endothelial cells from nearby capillaries or venues. These
endothelial cells will form the tumour vascular network (angiogenesis), which 'feed'
the tumour allowing it to grow in size. Then, across the newly formed blood vessel
wall, two-way invasive processes occur. In one direction immune cells egress from
the vessels to infiltrate the primary tumour, in the other direction tumour cells
penetrate into the capillary lumen (intravasation) and into the systemic circulation
through the blood or lymphatic vessel. Finally, some of these malignant cells arrest in
capillary beds at sites distant from the primary tumour. Here they may invade through
vessel walls again (extravasation) into the surrounding tissue and form secondary
tumours, i.e. metastases (Poste and Fidler, 1980).

D
Figure 1.1 Multiple processes of human cancer metastastasis. (A) Invasion,
(B) Angiogenesis, (C) Intravasion, (D) Extravasion and Metastasis formation.

1.1.2 The degradation of extracellular matrix (ECM) and human cancer invasion
and metastasis

Physiological invasive processes occur in the embryo and in the adult organism; e.g.,
during trophoblast

implantation,

formation of blood vessels

(angiogenesis),

extravasion of leukocytes in inflammation, and wound repair. Under pathological
conditions invasion is a recurrent theme in the natural history of malignant tumour
metastasis processes. A common feature of physiological and pathological cellular
invasive processes is the ability of cells to cross biological barriers that are present at
the interface between histologically distinct tissues. These include basement
membranes (BM), such as are located at the dermal-epidermal junction and beneath
capillary endothelium, and interstitial stroma, which is mostly represented in
mesenchymal tissue (Poste and Fidler, 1980). BMs and interstitial stroma are highly
organised structures composed of extracellular matrix (ECM), the components of
which are secreted by neighbouring cells. These components include collagens (the
major constituents of ECM and a family of fibrous proteins), glycoproteins (such as
laminin, fibronectin, entactin and nidogen), proteoglycans, and glycosaminoglycans
(Mignatti and Rifkin, 1993). The interaction of cells with ECM modulate cell
adhesion, differentiation and morphogenesis, mitogenesis, cell motility, as well as
selective exchange of molecules between cells and interstitial fluids (Farquahr, 1981).
The degradation of ECM components during physiological and pathological invasive
processes requires specific proteolytic enzymes (see review in Mignatti and Rifkin,
1993).

The ECM degrading proteinases can be subdivided into three classes: serine

proteinases, metalloproteinases and cysteine proteinases. The serine proteinases
include plasminogen activators (PAs), plasmin, leukocyte elastase, and cathepsin G.
The PAs of the plasminogen activation proteolytic cascade system appear to play an
important role in the processes of malignant cell invasion and metastasis (see section
1.3 for detail). The PAs convert the zymogen plasminogen, a plasma protein
ubiquitous in the body, to plasmin (see section 1.2.3 for detail). Plasmin is an enzyme
with broad trypsinlike substrate specificity. In addition to its major role in blood in
dissolving fibrin clots, it is also able to directly degrade several ECM components
including proteoglycans, fibronectin, laminin, and type IV collagen (Plow et al.,
1991). Furthermore plasmin can directly activate pro-metalloproteinases (Carroll and
Binder, 1999), the active forms of which degrade different collagen types, laminin,
fibronectin, elastin and proteoglycans of ECM. Thus, plasmin initiates a potent
proteolytic cascade and there is much evidence to indicate that the extracellular
plasminogen activation cascade facilitates cancer cell invasion and metastasis via its
pivotal role in ECM degradation. Prior to discussing the evidence for this, the
components of the cascade will be described in detail below.

1.2 THE PLASMINOGEN ACTIVATION CASCADE SYSTEM

1.2.1 Overview of the plasminogen activation cascade system

The plasminogen activation cascade is a complicated system of zymogens, active
enzymes, activators, inhibitors and binding proteins, which interact in a highly
organized manner to generate and subsequently regulate the broad spectrum serine
protease, plasmin. This system functions primarily in fibrinolysis and extracellular

matrix degradation. It is of central importance in the maintenance of proper
haemostasis after blood coagulation, specifically in facilitating vascular fibrinolysis
and in the control of wound healing (Binder, 1995). While the extent which this
system contributes to other normal physiological processes such as ovulation, fertility,
and embryogenesis is in question, as judged by results obtained with so called 'knock
out" mice (Carmeliet et al., 1994; Bugge et al., 1995), there is abundant evidence that
the coordinated expression of components of this system by both malignant tumour
cells and normal cells within the local environment allows successful cancer cell
invasion and metastasis (Dano et al., 1985, Andreasen et al, 1997) (refer to section
1.3 for detail).

1.2.2 Plasminogen

Plasminogen is present in blood and most extracellular fluids. It is synthesized in the
liver (Raum et al., 1980), and is maintained at a stable plasma concentration of 2.0
|iM (Ponting et al., 1992). Native human plasminogen is synthesized as a single chain
glycoprotein containing 810 amino acids, from which a 19-residue signal peptide is
excised during secretion. The mature form of plasminogen is therefore 790 amino
acids in length, with a molecular weight of 92 kDa and a glutamic acid residue at the
amino terminus (referred to glu-plasminogen) (Sottrup-Jensen et al., 1978).
Circulating human glu-plasminogen is glycosylated with an 0-linked tetrasaccharide
at Thr346, whilst differential N-linked glycosylation at Asn289 produces two
glycoforms (Hayes and Castellino, 1979). This difference in glycosylation influences
the affinity of plasminogen for fibrin, a2-antiplasmin and cellular receptors and also
its rate of activation (Ponting et al., 1992).

Various aspects of the biological activity of plasminogen are facilitated by three
distinct protein domains. First is a 12KDa N-terminal pre-activation domain, which is
critical for maintenance of the tightly closed spiral conformation of circulating gluplasminogen through non-covalent interactions with other domains of the protein (see
review in Ponting et aL, 1992). Removal of this domain via plasmin or urokinase type
plasminogen activator (uPA) catalyzed proteolysis at positions Arg67-Met68, LysyeLys77, and Lysvv-Valvg results in formation of the second in vivo species of
plasminogen known as lys-plasminogen. Lys-plasminogen has a more open
conformation than glu-plasminogen and hence a faster activation rate and higher
specific activity once converted to plasmin (Hoylaerts et al., 1982; also see review in
Ponting et al., 1992). Secondly, binding of plasminogen to various cellular receptors
and ECM proteins is mediated by lysine binding site (LBS) motifs found in the five
triple disulfide-bonded loop structures known as kringles in the plasminogen binding
domain (Sottrup-Jensen et al., 1978). Thirdly, the C-terminal 230 amino acids of
plasminogen, known as the protease domain, contain the plasmin catalytic triad
(His602, Asp645, Ser74o) which hydrolyses peptide bonds on the C-terminal side of
lysine or arginine residues (see review in Ponting et al., 1992). Activation of the
inactive zymogen (i.e. plasminogen) to active plasmin is facilitated by cleavage of
plasminogen at Argseo-Valsei by plasminogen activators, forming a twin chain
molecule composed of a heavy chain (65KDa, containing the pre-activation and
kringle domains) disulfide bonded to a light chain (25KDa, containing protease
domain) (Pollanen et al., 1991).

1.2.3 Plasminogen activators (PAs)

Plasminogen activators (PAs) are enzymes capable of promoting the conversion of
inactive zymogen plasminogen to its active form plasmin. They are found in most
tissues and body fluid in two major characterized forms: urokinase-type (uPA) and
tissue-type (tPA) plasminogen activators. Other plasminogen activators include
bacterial streptokinase and staphylokinase, and some other vertebrate plasminogen
activators (Dano et al., 1985).

These two major PAs belong to the family of serine proteases. They are encoded by
different genes and have distinctive structural and functional properties, despite
showing 40% homology at the amino acid level (Degen et al., 1991). The u-PA gene
is located on chromosome 8, and that of t-PA on chromosome 10 (Rajput et al., 1985).
These genes encode a 2.5kb mRNA which is translated into a 53 KDa glycoprotein
for uPA, and a 2.7 kb mRNA which is translated into a 70 KDa glycoprotein for tPA.
Structural differences between uPA and tPA include the absence of the second kringle
domain in uPA and the 43-residue-amino-terminal finger domain present in tPA (van
Zonneved et al., 1986).

Both PAs are produced as inactive single chain zymogens (sc-uPA and sc-tPA) which
are activated via cleavage by plasmin and other proteases to the active two-chain form
PAs (tc-uPA and tc-tPA). The conversion of sc-uPA to an active tc-uPA occurs by
cleavage of the peptide bond Lysisg-Heisg (Pollanen et al., 1991). In vitro, this
conversion has been reported to be catalyzed by a number of different proteinases.
These include plasmin (Dano et al., 1985), plasma kallikrein and blood coagulation
factor Villa (Ichinose et al., 1986), T cell associated serine proteinase (Brunner et al.,
1990), cathepsin B (Kobayashi et al., 1991), cathepsin L (Goretzki et al., 1992), and

human mast cell tryptase (Stack and Johnson, 1994). The conversion of the virtually
inactive sc-uPA to the active tc-uPA by catalytic amounts of plasmin is a crucial
regulatory step in the uPA pathway of plasminogen activation, since it not only
provides active uPA but also enables an autocatalytic acceleration of uPA formation
(Mayer, 1990).

uPA binds to specific cell membrane-anchored receptors (uPAR) and is therefore
primarily involved in cell based proteolysis that entail dissolution of ECM. The active
tc-uPA consists of a light 'A chain corresponding to its amino terminal region and a
heavy carboxy terminal 'B' chain linked together by a disulfide bridge (Dano et al.,
1985). 'A chain has a kringle domain and a growth-factor-like domain (termed K-G
subunits), corresponding 'B' chain has the catalytic serine protease domain (PD).
Following an additional proteolytic process, tc-uPA is further cleaved into an amino
terminal fragment (ATF) and low molecular weight uPA (LMW-uPA). Whereas
LMW-uPA is primarily involved in cellular proteolysis, tissue remodeling, embryonic
development, zymogen and growth factor activation to promote tumour invasion and
metastasis, ATF following its binding to uPA cell surface receptor (uPAR) can
promote cell proliferation, migration and adhesion (Fig. 1.2).
^ Proteolysis
sc-uPA
^ Tissue remodelling
^ Embryonic development
LMW-uPA
• Zymogen and growth factor activation
^ C a n c e r invasion a n d m e t a s t a s i s
tc-uPA

y

•
ATF

• uPAR activation

Cell proliferation
Cell migration
Cell adhesion

Fig 1.2 Model of processing and function of urokinase plasminogen activator (uPA).
The single chain uPA (sc-uPA) is converted into two chain uPA (tc-uPA) which undergoes
another step of proteolysis to form low molecular weight uPA (LMW-uPA) and its amino
terminal fragment (ATF) to elicit diverse effects either directly or following the binding of
ATF with uPAR

The central role of the uPA in tumour biology is becoming more and more evident and
considered important in local tumour growth, invasion and metastasis (Duffy, 1993)
(also see section 1.3).

Fibrinolysis is another in vivo function of the plasminogen system. tPA primarily
functions in this process by which fibrin is removed from the intravascular system
after it has completed its homeostatic task (Dano et al., 1985), as tPA must be bound
to fibrin for its full activity to be expressed (Chucholowski et al., 1991).

PA expression and activity can be regulated at many levels. Numerous hormones,
growth factors, and cytokines, exhibiting a wide variation that is dependent on cell or
tissue type studied, govern synthesis and release of both PAs (Pollanen et al., 1991).
Upon secretion, PA activity can be regulated positively or negatively by different
components (Carrol and Binder, 1999). PAs activity is subject to a variety of specific
and fast acting serine protease inhibitors (serpins) present in the extracellular fluid
referred to as plasminogen activator inhibitors (PAIs) (Pollanen et al., 1991).

1.2.4 Plasminogen activator inhibitors (PAIs)

1.2.4.1 Overview

hi the extracellular compartment, the secreted plasminogen activators (PAs) become
subject to the specific, fast acting plasminogen activator inhibitors (PAIs). Currently
there are four classes of PAIs: PAI-1, PAI-2, PAI-3 (or named Protein C Inhibitor,
PCI), and protease nexin 1 (PN-1) (Pollanen et al., 1991). The PAIs belong to the

serin protease inhibitors (serpins) superfamily, and are placed in the arginine-serpin
subgroup due to the arginine (Arg) residue at PI position of their reactive centers.
Despite uncertainty over the precise nature of the serpin inhibitory mechanism, it is
clear that inhibition involves insertion of the reactive center loop (RCL) into p-sheet
A of the serpin and transition to a more stable thermodynamic state, known as the
relaxed form of the inhibitor (Gettins et al., 1992). Of these four classes, PAI-1 and
PAI-2 are highly specific for PAs when compared to PAI-3 and PN-1, which both
have broader specificity profiles (Pollanen et al., 1991).

PAI-1 and PAI-2 have many different properties and these are presented in Table 1.1.
PAI-1 inhibits single-chain tPA (sc-tPA), two-chain tPA (tc-tPA), and two-chain uPA
(tc-uPA), but not single chain-uPA (sc-uPA), by forming tight sodium dodecyl sulfate
(SDS) stable 1:1 molar complexes in a very fast reaction involving the active site of
the enzyme (Pollanen et al., 1991). PAI-2 is an efficient inhibitor of active tc-uPA,
forming a slowly dissociable SDS-stable 1:1 complex with uPA (rate constant 1x10^
(Kruithof et al., 1995). Since fibrin-bound tPA is protected from inhibition by
PAI-2 and is 10,000 times slower in inhibiting sc-tPA than PAI-1, PAI-2 is probably
less likely to be involved in the physiological regulation of tPA (Kruithof et al., 1995).

Table 1.1 Comparison of human PAI-1 and PAI-2 properties (modified from
Pollanen et al., 1991)

Characteristic

PAI-1

Molecular weight

46-47 KDa

PAI-2
47 KDa (intracellular)
60 KDa (glycosylated)

Amino acid residues

379

415

mRNA

3.0/2.2 Kb

2.0 Kb

Chromosomal site

7

18q21-2

Synthesized by

Endothehal cells,

Placental trophoblasts,

Many types of cells

monocytes, etc.

Principal enzyme specificity

tPA and uPA

uPA

Binding protein

Vitronectin

None known

Latent inactive foiui

Yes

No

Effect of sodium dodecyl sulfate

Reactivates

Inactivates

Increased plasma concentrations

Septic Shock

Pregnancy

m

3 0009 03254798 1

1.2.4.2 Plasminogen activator inhibitor type 1 (PAI-1)

PAI-1 is a single chain 46 to 54 kDa glycoprotein encoded by 3.0 and 2.2 kb mRNAs,
the shorter transcript possibly being generated by modified polyadenylation. The
human PAI-1 gene of 12.2 kb is located on chromosome 7. The amino acid sequence
deduced from the PAI-lcDNA contains 379 residues, three potential glycosylation
sites, but no cysteine residues (Pollanen et al., 1991).

PAI-1 has significant homology with members of the serpins family. Like other
serpins, PAI-1 has a reactive center located on a highly strained, exposed loop, the
RCL, near the C-terminus of the molecule. The 'reactive center' of PAI-lcontains the
'bait' peptide bond between residues Arg346 and Met347, i.e. the P l - P l ' residues. This
bond mimics the Argseo-Valsei bond of plasminogen, which is the bond cleaved by the
plasminogen activators during the activation of plasminogen to plasmin. On the basis
of the mechanism of the action of other serpins, it has been postulated that PAI-1
binds specifically to the plasminogen activators like substrates (Seetharm R, 1992).

PAI-1 is secreted as an active antiprotease, but it rapidly, spontaneously converts to an
inactive latent form. Latent PAI-1 is uncleaved but does not show any inhibitory
activity towards target protease, i.e., tPA. In this state, the reactive center loop of PAI1 forms a sixth and central strand (known as s4A) of (3 sheet A, which is now
inaccessible to target protease. However, the term 'latent' is used because inhibitory
activity can be regained after a cycle of denaturation and renaturation (Tucker et al.,
1995). Indeed this structure is superimposable on the structure of cleaved aiantitrypsin with the exception that the P l - P l ' bond is still intact (Gettins et al., 1992).

Active PAI-1 could be stored at -70°C for months with minimal loss in its activity and
negligible conversion to the latent form. However, the PAI-1 lost about 50% of its
activity after 2 days at 25

or after 2 hours at 37

due to conversion to the latent

form. Significant conversion to the latent form also occurred at 4

(Seetharm, 1992,

Reilly et al., 1990).
PAI-1 is produced by many cell types such as endothelial cells, fibroblasts, vascular
smooth muscle cells, hepatocytes, hepatoma cells, mammary cells, melanoma cells,
fibrosarcoma cells and platelets et al. (Loskutoff, 1991). It is also present in plasma
(Andreasen et al., 1990). PAI-1 is found associated with vitronectin in plasma
(Preissner et al., 1993) and ECM (Ciambrone and McKeown-Longo, 1990). The
somatomedin B domain of vitronectin was identified as the PAI-1 binding site
(Seiffert and Loskutoff, 1991). Binding of vitronectin not only stabilized PAI-1 in an
active configuration (presumably by holding the loop out of the A sheet), but also
conferred on PAI-1 other inhibitory properties such as binding to thrombin (Pollanen
etal., 1991).
PAI-1 accumulates in the ECM and can be significantly enhanced by exposure of cells
to hormones and growth factors (such as transforming growth factor a, TGF-a)
(Laiho M et al., 1986). In fact, PAI-1 secretion and/or gene expression have been
demonstrated to be regulated by several effectors, many of which regulate the
expression of PAs as well. They include interleukin-1, thrombin, bacterial endotoxin,
basic fibroblast growth factor, phorbol myristate acetate, dexamethasone, tumour
necrosis factor a, and platelet-derived growth factor etc.. PAI-1 appears to be the
primary regulator of fibrinolysis in the vasculature. The increased plasma amounts of

il
PAI-1 and PAI-2 during normal pregnancy probably contribute to the maintenance of
the overall balance of the fibrinolytic system, as uPA and tPA concentrations are
increased as well. High levels of PAI-1 were detected in the plasma of patients with
severe preeclampsia, with a positive correlation to the severity of placental damage,
and with adult repiratory distress syndrome (Pollanen et al., 1991).

1.2.4.3 Plasminogen activator inhibitor type 2 (PAI-2)

PAI-2 was originally reported to be produced in the placenta and by cells of the
monocyte / macrophage lineage (Pollanen et al., 1991). However, recent studies have
shown that PAI-2 is expressed by many cell types. These include stimulated human
endothelial cells (Schleef et al., 1988), cultured vascular smooth muscle cells (Laug et
al., 1989), fibroblasts from fetal lung and foreskin (Kumar et al., 1992), normal
human epidermis and cultured epidermal keratinocytes (Jensen et al., 1995), epithelial
cells of the murine hair follicle and nail apparatus (Lavker et al., 1998), and numerous
other stratified squamous epithelial cells (Risse et al., 1998). Under normal conditions
levels of PAI-2 in plasma or serum are below detection limits. Initially detectable PAI2 was consistently found in blood plasma during pregnancy (Nilsson et al., 1986),
more recent findings suggest a much wider tissue distribution than initially thought.
These include dermal and epidermal layers of the skin (Lyons-Giorgano et al., 1994),
blood plasma in patients with myelomonocytic and acute monocytic leukaemia (Wada
et al., 1993) and with various liver diseases (Leiper et al., 1994), human gingival
cervicular fluid and whole saliva (Kinnby B, 1993).

The PAI-2 gene is located on the long arm of chromosome 18 between bands q21-23.

It spans 16.5 kb and has eight exons and seven introns. When compared to the genes
of two other serpins, PAI-1 and ovalbumin, the PAI-2 gene is shown to be
significantly different to the gene encoding PAI-1 but has a very similar structure
(37% homology) to that of hen ovalbumin gene (Webb et al, 1987, Ye et al., 1989).
The PAI-2 cDNA encodes a mRNA transcript of approximately 2.0 kb. PAI-2
expression can be regulated at both gene level and mRNA level. This expression is
modulated by a large number of factors including cytokines, growth factors and
hormones (Kruithof et al., 1995) (Fig. 1.3).
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Figure 1.3 Factors influencing PAI-2 gene expression.
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The primary structure of human PAI-2 is a single chain polypeptide comprised of 415
amino acids with a characteristic serpin reactive center formed by the Arg380-Thr381
bond (Fig. 1.4) (Antalis et al., 1988). It is an alpha globulin molecule that is stable at
pH 5.0-7.5 and exits in two distinct isoforms, both expressing inhibitory activities.
These are a non-glycosylated 47 kDa form, mainly found intracellularly, with an
isoelectric point of 5.0, and a 60 kDa glycosylated form, mainly found extracellular,
with an isoelectric point of 4.4 (Mikus et al., 1993). Both the cytosolic and secreted
forms are encoded by same 2.0 Kb mRNA, a process referred to as co-translational
facultative translocation (Belin, 1993). The relative distribution of the two forms of
PAI-2 seems dependent on cell type and differentiation state as well as culture
conditions (Mikus et al., 1993). Localization of active PAI-2 to a third topological
location, the surface of many non-transformed cell types (e.g. keratinocytes,
trophoblasts) has also recently been described (Kruithof et al., 1995). The localization
of PAI-2 to more than one topological site may be the result of inefficient
translocation of the protein into the secretary pathway. Secreted proteins generally
contain a hydrophobic signal sequence. PAI-2 is an exception as it contains an
uncleaved signal peptide. This signal sequence of PAI-2 contains an asparagine
hydrophobic core and two glutamine residues in the N-terminal region that dictates
poor secretion of the PAI-2 protein (Belin, 1993). Another unique protein feature of
PAI-2 is the presence of an extended loop between the C and D helices. The function
of this loop is unknown but it may be a functional domain that allows PAI-2 to take
part in binding reactions without affecting its inhibitory activity (Jenson et al., 1994).
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Figure 1.4 PAI-2 amino acid sequence. Positions of structural elements, e.g.
p-sheet strands, a-helices, C-D loop, RCL, and reactive bond, which is
designated by a dashed line between the PI (Argaso) and PI' (Thrsgi) residues
(SwissProt AC# P05120; Ye et al. 1987), are all shown as above.

Similar to other serpins, PAI-2 contains an reactive center loop (RCL) near the C
terminus which, on proteolytic cleavage, is inserted into central P-sheet A of PAI-2,
resulting in a conformational change from a stressed to relaxed (S-R) state
(Wilczynska M et al., 1995). When PAI-2 interacts with target proteases (e.g. uPA and
tPA), it is cleaved in its RCL by proteases, then a stable enzyme-inhibitor complex is
formed, and the proteases are irreversibly inhibited. PAI-2 may also be cleaved by a
proteinase that rapidly escapes from the inhibitor after cleavage, thus this protease
retains its proteolytic activity while generating an inactive inhibitor; in this case PAI-2
is acting not as an inhibitor but as a substrate of the protease (Kruithof et al., 1995). It
has been suggested by Kruithof et al. (1995) that the unexpected intracellular
localization of PAI-2 may be due to the interaction of PAI-2 with an unidentified
cytoplasmic protease. For instance, the corneal epithelial PAI-2 was shown to be
cleaved by an unidentified cytoplasmic protease (Williams, 1999).

Although the role of PAI-2 as the primary in vivo inhibitor of uPA is clear, the exact
physiological roles of PAI-2 in the modulation of proteolytic activity remain to be
clarified (Kruithof et al., 1995). PAI-2 (also PAI-1) antigen levels are known to rise
progressively throughout normal pregnancies resulting in a decrease of plasminogen
activation. Distinct PAI-2 and PAI-1 levels are noted in pregnancies complicated
preeclampsia (PE) and / or intrauterine growth retardation (lUGR). These differences
indicates that an increase in PAI-1 plasma level may act as a marker for PE, while
decreased PAI-2 plasma level as a marker for lUGR (Kruithof et al., 1995). PAI-2
may be involved in other physiological and pathological events, in which uPAmediated proteolysis plays an important role, including tissue remodeling, wound
healing, epidermal differentiation, leukocyte migration, programmed cell death (i.e.

apoptosis), inflammation and mmour invasion (Kruithof et al., 1995) (see section 1.3
& 1.4 for detail).

1.2.5

Urokinase plasminogen activator receptor (uPAR)

The cell surface uPAR has been isolated from human and rodent cell lines (Rabbani et
al., 1994; Roldan et al., 1990). The gene encoding uPAR located on the long arm of
chromosome 19 can express multiple isoforms of uPAR due to alternate splicing.
uPAR is a 50-60kDa cysteine rich highly glycosylated protein. Due to the presence of
cysteine residues, uPAR can be divided into three domains, domain 1, 2 and 3 as
numbered from the amino-terminal, which are homologous to other members of GPI
anchored proteins such as LY-6, squid glycoprotein (SgP-2), and viral protein HVS-5
(Dano et al., 1994). It is linked to the plasma membrane by the glycosyl
phosphatidylinositol (GPI) anchor located in its carboxyl-terminal domain 3 (Fig. 1.6;
Plough et al., 1991).

Binding of uPA to its speciñc cell surface GPI anchored receptors (uPAR) is
important for the localization of uPA catalyzed plasminogen activation. Binding is
rapid, saturable, and with a high affinity of 10"^° M. The binding of uPA to the
receptor occurs at its growth factor domain in the ' A chain (as described in section
1.2.2); it does not involve the catalytic site of uPA. Single chain uPA (sc-uPA) binding
to the cellular receptors is followed by conversion of the bound enzyme to active twochain uPA (tc-uPA) on the cell surface (Fig. 1.6). Therefore receptor bound uPA
retains its enzymatic activity and still maintains its susceptibility to be inhibited by
PAI-1 or PAI-2 (Mayer, 1990). PAI-1 and PAI-2 will bind to the cell surface

associated uPA-uPAR complex by forming an enzymatically inactive trimeric
receptor-protease-inhibitor complex. Then the PAIs trigger a series of events leading
to the internalization of the uPA-uPAR-PAI complex. The complex would be degraded
in the lysosomes and the uPAR is recycled back to cell surface (Nykjaer et al., 1997;
Mignatti et al., 1993).

tc-uPA

sc-uPA
GN

uPAR
Signal transduction

uPAR
Cell membrane

Figure 1.5 The structure and interactions of human uPAR with sc-uPA and

tc-uPA on cell surface. Human uPAR contains 3 domains (numbered as 1, 2
and 3 from N-terminus). The C-terminus of uPAR is attached to the cell
membrane via a GPI anchor, which may be involved in intracellular signal
transduction. The domain 1 contains binding sites for single-chain and twochain uPA (sc-uPA and tc-uPA). uPA contains 3 domains: G, growth domain;
K, kringle domain; SPD, serine proteinase domain. After binding to the domain
1 of uPAR on the cell surface, sc-uPA is cleavaged by plasmin and other
proteinase at the peptide bond of Lysl58-Ilel59. This cleavage forms the active
tc-uPA that contains two chains of polypeptides, the SPD and K-G subunits,
linked by a disulfide bond. Cell surface receptor bound uPA is functional in
activation of plasminogen to plasmin during focalised extracellular proteolysis
(modified from Behrendt et al., 1991).

1.2.6 Regulation of plasmin generation

The broad substrate specificity of plasmin means strict control is required to limit
activation to only physiologically appropriate times and sites. Regulation of plasmin
generation by the plasminogen

activation system is therefore intricate and

multifaceted at multiple levels including gene translation, pro-enzyme secretion, etc..
At the level of activation, not only can plasminogen activators' activity be regulated
either positively (as fibrin or cell surface receptors) or negatively (as PAIs), but also
the local microenvironment plays an important role. Inhibitors of plasmin also exist:
a2-antiplasmin, a2-plasmin inhibitor (a2-PI) and a2-macroglobulin (a2-M) are fast
acting protease inhibitors, which rapidly inactivate any plasmin found free in solution
(Veronica and Bernd, 1999). The presence of these circulating inhibitors may limit the
physiological effectiveness of any plasmin-mediated extracellular activation events,
however, local concentrations of plasmin may be sufficiently high to overcome local
levels of inhibitors, permitting pericellular activation (Castellino, 1995).

A second component of plasmin regulation involves manipulating the amount of
plasminogen available for activation to plasmin (Castellino,

1995). Invasive

procedures such as surgery or the use of oral contraceptives result in a decrease in the
amount of circulating histidine-rich glycoprotein, a plasminogen binding protein
known to reversibly bind 40% of the circulating plasminogen, thereby causing an
increase in the amount of plasminogen available for activation to plasmin (Castellino,
1995).

A third element of plasmin regulation involves the cell surface plasminogen receptors

and uPA receptor (uPAR) (Vaheri et al., 1990). The existence of plasma membrane
binding sites for uPA, plasminogen and plasmin points to the cell surface as the site of
assemblage of a powerful proteolytic system. Two steps in the urokinase plasminogen
activation system are dramatically enhanced by this process. Firstly activation of scuPA is markedly increased when it is receptor-bound and when plasminogen is
simultaneously present on the cell surface, and this in turn accelerates plasmin
formation (Ellis et al., 1989). Plasmin on the cell surface is protected from a2antiplasmin in plasma and extracellular fluids (Plow and Miles, 1990). Taken together,
these observations suggest plasmin generation and activity can be focused to
restricted domains of the cellular environment, such as the leading edge of migrating
cancer cells.
In the fibrinolytic system, plasminogen is bound to a solid fibrin substrate on the
thrombus in a specific interaction through the lysine binding sites, allowing plasmin
to be formed in situ and thus to escape the inhibitory effect of circulating plasma
inhibitors (such as: a2-antiplasmin and a2-macroglobulin). Interaction by plasma
inhibitors depends on the same kringle interactions as are involved in fibrin or cell
binding. Plasminogen has been shown to interact in vitro with the surfaces of
numerous human cell lines including endothelial cells (Cesarman et al., 1994),
monocytoid cells (Miles et al., 1991), neurons (Parkkinen et al., 1991) and tumour
cells such as human breast cancer cells (Ranson et al., 1998), fibrosarcoma cells,
osteosarcoma cells, leukemic cells and glioma cells (Plow et al., 1995). Additionally,
the binding of plasminogen to the cell surface enhances the rate of plasminogen
activation whilst affording protection of cell-localized plasmin from its specific
plasma inhibitor, a2-antiplasmin (Ponting et al., 1992).
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Binding of plasminogen to various cellular receptors is mediated by lysine binding
site motifs found in the five triple disulfide-bonded loop structures known as kringles
in its binding domain (also see section 1.2.2). Plasminogen interacts with cell surface
proteinaceous and non-proteinaceous moieties (Miles et al., 1991). The binding of
plasminogen to intact cell could be reduced when lysine analogues are present at the
same time (Ranson et al., 1998). Although this does not completely inhibit the
interaction, plasminogen characteristically binds to cells with low affinity (Kd range:
0.1-2 |iM) in a lysine-dependent manner and with relatively large numbers of binding
sites per cell (Plow and Miles, 1990). Thus the pericellular binding sites could provide
a means of recruiting plasminogen for focalized extracellular proteolysis, and this cell
surface localization of plasminogen would facilitate cell migration. To date, nine
heterogeneous candidate cell surface plasminogen binding proteins have been
identified and six other proteins remain essentially unidentified and uncharacterized
(Plow et al., 1995).

The activation of uPAR-bound sc-uPA has been found to occur much faster than
unbound sc-uPA (Ellis et al., 1989; Duval-Jobe and Parmely, 1994). This indicates
that uPAR may play an important role in regulation of uPA activation. Subsequently,
the levels of uPAR have a major effect on the generation of plasmin and the ability of
cells to degrade the surrounding ECM. Since GPI molecules have been known to
relay intracellular signal transduction, it is possible that uPAR may also be involved in
cellular signal transduction. uPAR not only binds uPA but is also a major binding
protein of vitronectin in ECM, thus altering the cellular morphology and its adhesive
properties (Kanse et al., 1996; Wei et al., 1996).
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The role of uPA-uPAR complex in thrombosis and homeostasis is supported by severe
thrombosis seen in plasminogen-deficient mice and in a high percentage of uPA
'knock out' animals (Carmeliet et aL, 1994). A functional uPA-uPAR interaction is
also required for tumour cell penetration of fibrin, activation of plasminogen and
other proteases to breakdown ECM, which facilitate tumour growth and metastases
(Bugge et aL, 1995). Elucidation of the role of uPA-uPAR in tumour progression over
the last few years and its usefulness as a prognostic marker to follow disease
progression has resulted in the establishment of uPA-uPAR as a potential target for
anticancer therapy (see section 1.3 & 1.4 for detail).

1.3 PLASMINOGEN ACTIVATION CASCADE SYSTEM AND HUMAN
CANCER

As described in section 1.1, during human cancer invasion and metastasis, malignant
tumour cells cross extracellular biological barriers by attachment to and interaction
with components of the ECM, and by local proteolysis. While the tPA activation
system plays the key role in fibrinolysis, the uPA activation system is primarily
involved in pericellular proteolysis. Strong experimental and clinical evidence has
accumulated that the tumour-associated plasmin, uPA, uPAR, PAI-1 and PAI-2 are
linked to cancer invasion and metastasis.

1.3.1 The dynamic regulation of the plasminogen activation cascade system on
the malignant cell surface
As described above, the cell surface is the site of assemblage of a powerful urokinase
plasminogen activation proteolytic system. Cell surface receptors of proteases, their

inhibitors and specific interaction between proteases are tightly regulated in this
system under physiological and pathological conditions. The general organization of
this system on malignant cell surface is summarized in Fig. 1.6.

Tissue breakdown & migration

^ a2-antiplasmin

Figure 1.6 The general organization model of the malignant tumour cell
surface urokinase plasminogen activation system. Pig, plasminogen. Pn,
plasmin. After uPA-uPAR-PAIs complex internalization, uPA & PAIs
degraded but uPAR recycled back to cell surface.
As described in Fig. 1.5 and 1.6, penetrating malignant tumour cells focus proteolytic
activity to the cell surface through receptors for plasminogen / plasmin and uPA. The
uPAR on the tumour cell surface binds sc-uPA released from surrounding tumour cells
and stroma cells (Ploug et al., 1991). This binding provides the malignant cells with a
potential proteolytic activity at a specific point, and enhances the rate of the
conversion from sc-uPA to active tc-uPA by a number of proteases including

kallikrein, cathepsin and cell surface bound active plasmin. This binding may also
induce cell adhesions and initiate a signal-transduction pathway via the GPI anchor of
uPAR. Active tc-uPA catalyses activation of plasminogen to plasmin at the cell
surface.

The activation of receptor bound plasminogen to plasmin is enhanced as cell surface
bound plasmin is protected from circulating inhibitors (e.g. a2-antiplasmin). Active
cell surface bound plasmin can then directly or indirectly catalyze the degradation of
E C M that facilitates malignant tumour cell proliferation, invasion and metastases (as
described in section 1.1.2). ECM degradation activity of the system is regulated by the
balances between levels of expression of components of the uPA system. High levels
of specific inhibitors, such as PAI-1, PAI-2 and a2-antiplasmin, can down-regulate the
E C M degradation activity of the system. While high levels of expression of uPA,
uPAR and plasminogen will increase the ECM degradation activity. Proteolytic action
of uPA is controlled by its inhibitors PAI-1 and PAI-2 which bind to the cell surface
associated uPA-uPAR complex forming an enzymatically inactive receptor-proteaseinhibitor complex which is internalized by the tumour cells (Conesi and Blasi, 1995).
It appears that the protease uPA and the inhibitor PAI-1 have to be present in the
tumour to achieve effective uPAR mediated limited proteolysis. The internalization
and recycling of uPAR may restore focalized cell surface-associated proteolytic
activity (Fig. 1.6) (Liu et al., 1995).

Expression levels of some components in the system, such as uPA, uPAR and PAI-1,
are regulated by a large variety of hormones, growth factors and cytokines (reviewed
by Besser et al., 1996). Oncogenic transformation of the cells may lead directly to an
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increase in expression of some components of the uPA system (Duffy, 1993).
Oncogenic transformation may also confer on cancer cells the ability to direct gene
expression of neighbouring cells (Anderasen et al., 1997). This may explain the upregulation of certain components of the system (e.g. cancer cell surface uPA-uPAR
complex) in some metastatic cancer cell lines.

1.3.2 uPA / uPAR and cancer

The uPA-uPAR interaction on cancer cell surfaces is a key event that results in
increased in vitro matrix degradation and migration (Duffy, 1993). In prostate cancer
cell lines, uPA was secreted in higher amounts in an invasive cell line as compared to
a noninvasive cell line and was immunohistochemically localized to the leading edge
of invasive cells (Gaylis et al., 1989). In human breast cancer cell lines, the metastatic
cell line MDA-MB-231 showed higher cell surface expression of uPA-uPAR,
significantly more cell surface bound plasminogen, and larger amount of plasmin
generating than non-metastatic cell lines MCF-7 and T-47-D (Long and Rose, 1996;
Ranson et al., 1998). Transfection of uPA or uPAR cDNA into the low uPA or uPAR
expressing human osteosarcoma cell line was found to increase uPA or uPAR
expression and enhanced its rate of ECM invasion (Kariko et al., 1993). Furthermore,
uPA cDNA transfection of rat prostate carcinoma cells enhanced their metastatic
potential in rats (Achbarou et al., 1994). Antibodies against uPA inhibited cell
invasion in vitro models (dayman et al, 1993; Reich et al., 1988; Mignatti et al.,
1986;). In experimental animal models, antibodies against uPA inhibited tumour
metastasis in the chick embryo (Ossowski, 1988), spontaneous metastasis in mice
(Kobayashi et al., 1994), and local invasion in nude mice (Ossowski et al., 1991).

Inhibition of uPA and / or uPAR expression by antisense sequence to uPA / uPAR
mRNA have been found to reduce the invasive capacity of human fibroblast cell
(Quattrone et aL, 1995). Also antisense uPA oligonucleotides reduced the spread of
human ovarian cancer in mice (Wilhelm et aL, 1995). Synthetic uPA inhibitors
reduced invasion and metastasis in a murine mammary tumour model (Alonso et aL,
1996).
All these findings from both in vitro and in vivo experiments suggested that cell
surface over-expression of uPA and / or uPAR will lead to an increase in the
metastatic capacity of the cancer cell lines. The clinical findings as to the extent of
involvement of uPA in tumour cell invasion and metastasis supported these
experimental studies.
Altered expression of uPA has been found in almost all types of human cancer by a
variety of techniques including cancer of the breast (Duffy et aL, 1988), prostate (Plas
et aL, 1998; Kircheimer et aL, 1985), cervix (Camiolo et aL, 1987), endometrium
(Bulletti et aL, 1991), ovary (Saito et aL, 1990), skin (Delbaldo et aL, 1994), colon
(Sier et aL, 1994), stomach (Nekarda et aL, 1994), bladder (Gorelik et aL, 1990),
kidney (Hofmann et aL, 1996), lung (Pedersen et aL, 1994), and leukemia (Wilson et
aL, 1992). Measurement of uPA in extracts of tumours from patients was found to
have prognostic significance for relapse in breast cancer (Foekens et aL, 1992; 1995),
colorectal cancer (Ganesh et aL, 1994), gastric cancer (Nekarda et aL, 1994), and
kidney cancer (Hofmann et aL, 1996). Similar to that already performed on uPA,
uPAR was subjected to an intensive clinical analysis in cancer patients. It has been
localized by in situ hybridization and immunohistochemistry in colon carcinoma
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(Pyke et al., 1994), in breast (Bianchi et al., 1994) and skin cancer (de Vries et al.,
1994). Measurement of uPAR in tumour tissue extracts was of prognostic value in
lung cancer (Pedersen et al., 1994-1) and renal cell carcinoma (Hofmann et al., 1996).
A ligand-free, soluble form of uPAR was found in the ascites fluid of ovarian cancer
patients (Pedersen et al., 1993). Therefore, these studies have shown that the levels of
uPA and uPAR expression are significantly associated with the metastatic capacity of
cancer cells.

1.3.3 PAI-1 and cancer

PAI-1 is the major plasminogen activator inhibitor in plasma and the endotheUum.
Although it plays the key role in fibrinolysis by regulating tPA, PAI-1 can bind active
tc-uPA and complex formation of uPA-uPAR-PAI-1 causes internalization and
degradation of the complex (Cubellis et al., 1990). Paradoxically, PAI-1 may be
directly involved in cancer progression, since tumour cells and capillary endothelial
cells express higher levels of PAI-1 than other cell types (Heiss et al., 1995). Evidence
from in situ and immunohistochemical studies support that PAI-1 was associated with
cancer progression. PAI-1 was detected in endothelial cells in colon cancer (Pyke et
al., 1991), was elevated in breast carcinoma tissue as compared to benign tissue
(Reilly et al., 1992), was expressed in melanocytic neoplasia (Delbaldo et al., 1994),
in liver cancer (Fitch et al., 1994), and immunohistochemically localized to primary
tumour and metastases of Lewis lung carcinoma (Kristensen et al., 1990).

PAI-I has been correlated with a poor prognosis for a variety of cancers including
pulmonary carcinoma (Pedersen et al., 1994-2), stomach cancer (Nekarda et al..
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1994), and renal cell carcinoma (Hofmann et al., 1996). Furthermore, metastasis of
ovarian cancer patients contained two fold more PAI-1 than the primary neoplasms
(Schmalfeldt et al., 1995). In colorectal cancer, eightfold more PAI-1 was determined
in liver metastases as compared with the primary tumour (Sier et al., 1994). Most
interesting of all was the clinical finding that tumour associated PAI-1 was an
independent and significant marker for recurrence in breast cancer (Foekens et al.,
1994).

In vitro studies, using a variety of cancer cell lines or experimental manipulation of
PAI-1 in cells, have given conflicting results. For example, Cajot et al. (1990) showed
that PAI-1 inhibited an invasive phenotype when fibrosarcoma and colon carcinoma
cells were transfected with PAI-1 cDNA, but Soff et al. (1995) showed that invasion
was not inhibited in PAI-1 transfected prostate cells as compared to control cells (Soff
et al., 1995). Matrix-bound PAI-1 inhibited the invasion of monocytes in vitro
(Kirchheimer et al., 1990), capillary tube formation in vitro in a dose dependent
manner (Schnaper et al., 1995), and tumour growth, angiogenesis and metastasis in
animal models (Soff et al., 1995; Ma et al., 1997; Jankun et al., 1997). However,
expression of PAI-1 along with uPA-uPAR facilitated optimum invasiveness of lung
cancer cells (Liu et al, 1995). Most surprising of all was the result that host-produced
PAI-1 is essential for cancer invasion and angiogenesis in a PAI-1 deficient (PAI-1')
mouse model (Bajou et al., 1998).

There is accumulating evidence that both uPAR and PAI-1 are multifunctional
proteins involved not only in ECM proteolysis, but also in cellular adhesion and
migration through their binding sites for vitronectin (Chapman et al., 1997). Due to

these recent developments, a shift in thinking of the significance of PAI-1 in tumour
pathogenesis has occurred. It has been suggested by Bajou et al. (1998) that
expression of PAI-1 along with uPA-uPAR and plasminogen probably facilitates
optimal cancer cell invasion and angiogenesis rather than unrestrained proteolysis.
Their experimental result, that the bioavaliability of PAI-1 to endothelial cells is
essential for capillary sprouting in tumour angiogenesis and as a consequence for
tumour cell invasion, might explain the paradoxical relationship between PAI-1, high
metastasis rate and poor survival in clinical findings.

1.3.4 PAI-2 and cancer

The exact role of PAI-2 in human cancer has not been explored deeply. To date most
work in this area has focussed on PAI-1 with firm correlation between high levels of
PAI-1, uPA and uPAR and a poor prognosis of cancer patients. However the exciting
potential of PAI-2 as a suitable therapeutic or diagnostic agent is now being
addressed.

The recent availability of substantial amounts of human recombinant PAI-2 has
allowed this serpin to be evaluated as a potential inhibitor of cell migration and
tumour cell invasion (Kruithof et al., 1995). Exogenously added recombinant PAI-2
inhibited the cancer cell plasminogen-dependent degradation of the subendothelial
cell basement membrane (Baker et al., 1990). Also PAI-2 inhibited degradation by
human

melanoma

cell M24met

more effectively than

tissue inhibitor

of

metalloproteinase type 2 (TIMP-2) (Montgomery et al., 1993). The role of PAI-2 was
further studied using stably transfected HT-1080 sarcoma cell clones. Expression of

recombinant PAI-2 in HT-1080 cells resulted in inhibition of ECM invasion in vitro
and induction of a thick peritumoral capsule formation in vivo (Laug et al., 1993). In
other animal models, human melanoma cells stably transfected with PAI-2 and
injected subcutaneously (s.c.) in severe combined immunodeficient (SCID) mice had
significantly less metastases in lung and lymph nodes than mock transfected control
melanoma cells (Mueller et al., 1995). Intraperitoneal (i.p.) injection of PAI-2 resulted
in a decrease of tumour mass after i.p. xenografting human A431 cells into nude mice,
whereas the plasmin inhibitor tranexamic acid had no beneficial effect (Shinkfield et
al., 1992). Daily intratumoral injection of PAI-2 into uPA producing DU-145
subcutaneous tumours in SCID mice significantly decreased tumour size (Billstrom et
al., 1994).

Elevated levels of uPA, uPAR and PAI-1, but low levels of PAI-2 in primary tumour
tissue clinically indicates poor prognosis, which mean shorter relapse free survival,
shorter metastatic disease free survival, and a shorter overall survival of cancer
patients (Duffy, 1996). A subgroup of breast cancer patients, characterized by high
levels in tumour extracts of uPA and PAI-1 and low level of PAI-2 was identified,
which had a very poor prognosis (Bouchet et al., 1994).

All these results suggest that human recombinant PAI-2 has exciting potentiality to be
used in a number of therapeutic applications for cancer. By virtue of its capacity to
inhibit one of the key enzyme protease cascades (i.e. urokinase plasminogen
activation cascade) responsible for ECM degradation and subsequent malignant
cellular invasion and metastasis, PAI-2 could be used as a promising anti-metastatic
agent in human cancer therapy. Pharmacokinetic studies investigating the potential
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use of PAI-2 as a cancer therapeutic agent showed promising results (Hang et al.
1998). Injection of

labeled human recombinant PAI-2 into nude mice xenografted

with the metastatic human colon cancer cell HCT-116 resulted in accumulation of
PAI-2 in the primary tumour with relatively rapid clearance from other organs. PAI-2
binding to HCT-116 cells in vitro could be blocked by specific inhibitors of uPA
activity and anti-uPA antibodies, indicating that localization to the primary tumour in
vivo may block uPA dependent proteolysis (Hang et al., 1998). This localization and
accumulation of PAI-2 in tumour tissues strongly argues for the potential therapeutic
use of PAI-2 in human cancer (further discussed in section 1.4).

1.4 TARGETED THERAPY AND HUMAN CANCER

1.4.1 Overview

Despite recent advances in characterizing the cell biological and molecular basis of
human cancers, their early detection with the aid of new imaging and diagnostic
techniques, and multiple traditional therapies, the mortality from most human cancers
is still high. The most important problem in the management of cancer is control of
metastatic

disease.

Traditional

human

cancer

therapies,

including

surgery,

chemotherapy and radiotherapy, are unable to control the distant metastasis due to
incompletely killing of invisible malignant tumour cells that have spread all over the
body in the later stage of cancers (Allen, 1999). An approach that has not been fully
developed to date that may overcome this problem is named "Targeted Therapy".
Targeted therapy, first developed at the turn of 20'^ century by Paul Erhilch, is based
on the idea that a drug will attack its target without damaging any other tissues (from

Raso V, 1990). Erhilch referred to the targeting drug as a "magic bullet" that must
contain a cancer localizing and medicament moiety. The medicament moiety could be
a toxin, drug or radionuclide that causes cell death. If by this idea the cytostatic
compound is specifically localized to malignant tumour cells but not normal cells, e.g.
haemopoietic cells of the bone marrow, the efficacy of human cancer management
could be substantially increased.

Since antibodies can specifically bind with high affinity to tumour associated antigens
on malignant cell surfaces, it is not surprising that antibody-medicament conjugates
were and are considered a way to increase the selectivity of cancer therapy. So far
most monoclonal antibodies applied in immunoconjugate research and clinical
applications are of murine origin due to difficulties in producing human antibodies of
a desired specificity and large quantities (James, 1990; Philip et al., 1997). This leads
to negative immunogenic side-effects from allergic reactions to anaphylactic shock in
some patients (Raso, 1990). Most seriously, patients who were not severely
immunosuppressed produced antibodies that bound to and neutralized the injected
murine monoclonal antibodies, thus making further therapy with the antibody
pointless (Philip et al., 1997).

In addition to the immunogenic reactions of murine monoclonal antibodies in humans,
other problems undermined the therapeutic value of the antibodies in anticancer
clinical trials. For example, the emergence of antigen-negative mutation on tumour
cells has limited the use of monoclonal antibodies. Anti-idiotype antibodies alone or
in combination with interferon-a produced only 15-25% complete remissions in
phase III clinical trials in "follicular lymphoma" patients. Most other patients had

marked temporary remissions curtailed by the emergence of idiotype-negative mutant
lymphoma cells as was seen in previous animal studies (Philip et al., 1997). Another
obstacle was the phenomenon of antigenic modulation on cancer cells. Most drug or
toxin conjugates act only within the cell. However internalization of cell surfaceattached antibodies does not necessarily happen in every case. Some cell surface
antigens, when cross-linked by antibodies, are shed from the cell surface (Philip et al.,
1997). This reduces the number of molecules of target antigen available for binding
by the antibody-medicament conjugates, and may allow the cell to escape killing as
the modulated antigen is re-expressed only when antibody is no longer present some
days later (Raso V, 1990; Philip et al., 1997). Furthermore, the effectiveness of the
antibody treatment was reduced by the formation of complexes between the infused
antibody and target antigens shed from the tumour cell surface. To date there is no
good solution to the problem of antigen shedding (Philip et al., 1997). Altogether,
these drawbacks of antibody treatments suggest that an alternative approach to
discriminating between malignant and normal cells in targeted anticancer therapy may
yield better results.
Three major steps should be considered in contemplating an ideal targeted therapeutic
modality. The first is to find and select a stable cancer marker (cell surface associated)
present in the human cancer to be targeted. The second step is to provide a special and
high affinity-binding component as a device to carry the cell-killing medicament and
bind the cell surface marker. Finally it is necessary to produce a suitable carriermedicament conjugate to effectively kill the targeted cancer cells and spare critical
normal cells.
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The most important consideration in the selection of a cancer marker is the number of
cancer cell types that express or overexpress it. It is very difficult to find one special
marker that is expressed by all cells in all kinds of human cancers. As discussed in
section 1.3, strong experimental and clinical evidence indicate that components of
plasminogen activation system: plasmin, uPA, uPAR and the inhibitor PAI-1 are
associated with many human cancers invasion and metastasis. Therefore, it seems
obvious that one or all of these components could be useful targeting markers in many
human cancer types.

1.4.2 Receptors bound uPA as a human cancer cell target: use of PAI-2 as a
targeting device

As described in section 1.3.2, uPA and / or uPAR are overexpressed on many human
cancer cells surface when compared with normal cells. Thus uPA and / or uPA/uPAR
complex could be targeted as a marker in anticancer therapy, using a ligand (amino
terminal fragment of uPA to target receptor) or polyclonal and monoclonal antibodies.
However utilization of these tumour localizing factors as target devices do not secure
internalization of conjugated cell-killing medicament, do not overcome the problems
of cancer cell surface antigen-negative mutation and antigenic modulation, and do not
overcome the negative immunogenic side effects of murine origin antibodies as
discussed in section 1.4.1.

Another promising method of delivering the medicament to cancer cells is to
conjugate medicament with human natural inhibitors of uPA: PAI-1 or PAI-2. Since
PAIs do not target specific cancer (like most antibody strategies), they could

potentially be used against a wide range of malignant human cancers wherever
cellular uPA overexpression is thought to play crucial roles in invasion and metastasis.
As proteins of human origin, PAIs are not immunogenic and therefore superior to
murine origin antibodies proposed for targeted human cancer therapy. PAIs
specifically bind to uPA/uPAR overexpressed on the surface of malignant cancer cells
with high affinity, after binding PAIs trigger internalization of the uPA-uPAR-PAIs
complex into the cancer cells (Cubellis et al., 1990; Jensen et al., 1990; Hang et al.,
1998; also see review in Kruithof et al., 1995; and review in Carroll and Binder,
1999). Thus, if a suitable lethal medicament is conjugated to PAIs, the uPA-uPARPAIs-medicament complex would localize to and be internalized into the targeted
cancer cells. After internalization, the complex is degraded, the receptors are recycled
(Nykjaer et al., 1997; also see review in Carroll and Binder, 1999), the product of
protein degradation and the medicament are released to the cytosol which secure and
increase the efficacy of medicament killing ability (Fig. 1.7).
Lethal Medicament

Targeted cancer cell

Figure 1.7 Model of the 'Magic bullet' in targeted anti-cancer therapy. Receptorbound uPA (uPA/uPAR) as a human cancer cell target. PAIs as a targeting device
carrying lethal medicament to kill the targeted cancer cells.

Although PAI-1 has been studied more extensively than PAI-2, unfortunately PAI-1 is
not a stable protein, as it spontaneously converts itself into a latent, inactive form

(Pollanen et aL, 1991). The latent form of PAI-1 does not possess the ability to bind
uPA and is therefore useless in targeted anticancer therapies (see section 1.2.4.2 for
detail). However, the modification of PAI-1 to prevent its conversion into the inactive
form has been tried. Jankun (1994) reported 4-succinimidyloxycarbonyl-a-methyl-a(2-pyridyldithio)-toluene (SMPT) modified PAI-1 conjugated with saporin in in vitro
cell-killing assays of the high uPA expressing HT1080 fibrosarcoma cell line and in in
vivo antitumour assays in HT1080 xenografted SCID mice. Results demonstrated the
effectiveness of PAI-1 in recognizing cancer cells and delivering the cytotoxic
compound into the cancer cells as a targeting device. But they found that both PAI-1
was heavy modified by SMPT. Furthermore, conjugation of SMPT-PAI-1 with
saporin also had serious negative effects on the activity of PAI-1 (Jankun, 1994).

On the other hand, PAI-2 has several distinct advantages compared with PAI-1. First
of all, PAI-2 is a stable protein, whereas PAI-1 is unstable and more sensitive to
oxidation (see section 1.2.4). Furthermore, in pregnant women sustained elevated
PAI-2 levels (at least up to 300 ng/ml) appear to have no systemic or pathologic
consequences (Kruithof et al., 1987), whereas sustained elevations of PAI-1 may be
thrombogenic (Erickson et al., 1990). Also PAI-2 is 10,000-fold less active toward sctPA than PAI-1, which allows for a larger window of efficient uPA inhibition (see
section 1.2.4). Finally, as mentioned in section 1.3.4 the localization and accumulation
of PAI-2 in tumour has been demonstrated in Hang (1998). Furthermore high doses of
I^^^ labeled PAI-2 (up to 500 ng/mouse) into these mice did not cause any side effects
(Hang et al., 1998). Thus the potential therapeutic value of PAI-2 in targeted
anticancer therapies is promising and demands further study.
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1.4.3 Animal model and targeted anti-cancer therapy

The preclinical experiments in targeted anticancer therapy need good in vivo animal
models that can mimic the natural history of human cancer invasion and metastasis.
By systemically introducing suitable targeting device-medicament conjugates into
these in vivo human cancer xenografted animal models, the efficacy of novel targeted
anti-cancer therapies before clinical trial in human beings may be assessed.

A major limitation of in vivo models for this study is the lack of the many host factors
that participate in the physiological and pathological mechanisms contributing to the
malignant phenotype. Only a few experimental models are available for in vivo
investigations of human cancer cell invasion and metastasis (Dagg et al., 1956;
Kozlowski et al., 1984). One suitable model for this study is the athymic nude mouse
(Fidler, 1986; Neulat-Duga et al., 1980). Most studies in this nude mouse model have
been based on injections of tumour cells intravenously, and this approach involves
only the later steps of the metastatic process. A subcutaneously inoculated or serially
transplanted tumour demonstrating local invasion and spontaneous metastatic spread
is a more adequate model for the invasive and metastatic behaviour of cancer cells.
However, there not only has been Umited success in establishing human tumour cell
lines that reproducibly spread in nude mice after subcutaneous inoculation, difficulties
in identifying small metastases throughout the mouse have also been a very
significant problem (Ossowski and Reich, 1980). A number of human melanoma cell
lines have been found to metastasise in nude mice, and the expression of melanin m
some of these melanoma cell lines facilitated the identification of metastasis in the
nude mice (Ishikawa et al., 1988). Unfortunately, melanin production is restricted to

certain malignancies, and therefore can not be used as a general marker for the
identification of human cancer cells in the nude mouse (Wilson et al., 1988).

Recently, Farina et al. (1998) developed a model that directly examines the motility of
metastatic primary tumour cells in situ. This is the first time that living primary
tumour cells in a live animal have been visualized as part of a chnically relevant
model. A metastatic rat breast cancer cell line MTLn3+GFP was established by green
fluorescent protein (GFP) gene transduction that constitutively expresses green
fluorescent protein in primary and metastatic tumours throughout the life span of the
animals injected. The fluorescent primary and metastatic tumours appear much
brighter than the background of host tissue under the light passed through an FITC
filter set. GFP expression in tumours was also confirmed by inmiunohistochemistry
with an anti-GFP polyclonal antibody. Animations of a single metastatic tumour cell
moving in live animals were generated by intravital imaging of the primary tumour in
situ on a laser scanning confocal microscope (Farina et al., 1998). Further
development of this interesting experiment may provide a novel method to access
human cancer invasion and metastasis in animal models.

1.5 AIMS

The overall aim of this project was to assess the viability of using PAI-2 as a targeting
device in future human targeted anti-cancer therapy projects.

The specific aims of this project were:

•

To confirm and determine the expression level of cell surface bound uPA of
human breast cancer cell lines HS-578-T, MDA-MB-231, MCF-7 and human
prostate cancer cell line PCS by flow cytometry.

•

To determine the cell surface expression level of endogenous PAI-2 of HS-578-T,
MDA-MB-231 and MCF-7; and exogenous PAI-2 binding of metastatic cell lines
HS-578-T and MDA-MB-231 by flow cytometry.

•

To produce stable transfection of

MDA-MB-231

with green fluorescent protein

(GFP) cDNA; and to check expression levels of uPA and GFP on transfected
MDA-MB-231-hGFP

•

cell surface.

To perform preliminary confocal microscopy to examine exogenous PAI-2
internalization by MDA-MB-231+GFP cells.

•

To develop in vivo breast cancer models by subcutaneous inoculation of MDAMB-231 and MDA-MB-231+GFP cells into mammary fat pads of nude mice.

2. MATERIAL AND METHODS

2.1 Cell culture

The human breast cancer cell hnes in this study (MDA-MB-231, MCF-7, HS-578-T)
and the human prostate cancer cell line PCS were all routinely cultured in RPMI-1640
supplemented with 10% (v/v) heat-inactivated fetal calf serum (PCS). The cells were
all incubated in a humidified incubator at 37^C with a 5% carbon dioxide: 95% air
atmosphere.

Human breast cancer cell lines (MDA-MB-231, MCF-7, HS-578-T) were from
American Tissue Culture Collection (ATCC), USA. Human prostate cancer cell line
PC3 was a gift from Professor Barry J Allen (St George Hospital Cancer Care Center,
Kogarah, NSW, Australia). RPMI-1640 was purchased from Trace Biosciences
(Castle Hill, NSW, Australia). PCS was obtained from CSL (Parkville, Victoria,
Australia).

2.2 Preparation of pEGFP-Nl for transfection of MDA-MB-231 cells

Green fluorescent protein (GPP) reporter gene was used in this study to produce a
heritable, stable volume marker of metastatic human breast cancer cell line MDAMB-231 that allows cells to be followed in the process of invasion and metastasis
after being xenografted into nude mice in the long term. The GPP gene has been
cloned in the mammalian expression N-terminal protein fusion vector pEGFP-Nl in
DH5a bacteria (purchased from CLONTECH, Palo Alto, CA, USA). The pEGFP-Nl
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vector contains a number of features including Pcmv, GFP reporter gene, selectable
marker NEO^ (neomycin resistance), and multiple cloning sites.
Single colonies of DH5a bacteria containing pEGFP-Nl were inoculated in 100ml LB
broth supplemented with 50 |ig/ml kanamycin, and grown overnight at 37°C with
shaking. The plasmid DNA was extracted and purified by Qiagen Plasmid Midi kit
(purchased from Qiagen, Pty Ltd., Clifton Hill, Victoria, Australia), following the
manufacturer's instruction, and stored at -20°C for later transfection of the human
breast cancer cell line MDA-MB-231. The yield and purification were determined by
U. V. spectrophotometry at 260 and 280 nm. Linearised pEGFP-Nl was produced by
digesting uncut supercoiled pEGFP-Nl DNA (~2 |Lig) samples with 1 jil Bgl 11
restriction endonuclease (Boehringer Mannheim Biochemica), 2 jil lOx incubation
buffer M (Boehringer Mannheim Biochemica), and 14 |il dH20 in a final 20 L| L1
volume at 37^C overnight. The original extracted DNA and the digestion sample were
examined by electrophoresis on 1% agarose in Ix TAE buffer at 60 V over 1 hour.
2.3 Stable transfection of adherent MDA-MB-231 cells with pEGFP-Nl plasmids
The adherent MDA-MB-231 cells were transfected with the linearised pEGFP-Nl
plasmid (-Ijig) using the SuperFect Transfection Reagent (STR) kit (purchased from
Qiagen Pty Ltd., Clifton Hill, Victoria, Australia). The experiment was carried out as
recommended by the protocol of the STR kit. The general principle of STR is that the
reagent is a specifically designed activated dendrimer that can form a complex with
DNA upon incubation at room temperature (20-25°C). The STR-DNA complexes
possess a net positive charge, which allows them to bind to the negatively charged

receptors (e.g. sialylated glycoproteins) on the surface of MDA-MB-231 cells in this
case. The STR-DNA complexes are then taken into the cells by endocytosis process
(Fig.2.1).
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Figure 2.1 The general principal of the SuperFect Transfection Reagent (STR) in
stable transfection of MDA-MB-231 cells with pEGFP-Nl plasmid.
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The efficiency of transfection of different cell lines with STR is dependent on a
number of parameters. Therefore, it is necessary to optimize these parameters to yield
high levels of transfection. Stable transfection of MDA-MB-231 was carried out to
optimize the ratio of the amount of STR to the amount of pEGFP-Nl DNA. This ratio
will determine the net charge of the STR-DNA complexes, which allows the
complexes to bind to the cell surface and to be taken up by the cells. As a sequence,
this ratio will determine the efficiency of transfection of the MDA-MB-231 cell line.
The optimization of the efficiency of the stable transfection experiment was
performed by following the STR kit (Qiagen) manufacturer's instructions as shown in
Table 2.1.

Table 2.1 Ratio of SuperFect Transfection Reagent (STR) to pEGFP-Nl DNA for
optimizing the efficiency of stable transfection of MDA-MB-231 cells (modified
from Qiagen manufacture's instructions).

Ratio of STR to DNA
0:1 2:1 4:1 6:1 8:1 10:1 4:0

Amount of DNA (^ig)

1

1

1

1

1

1

0

Amount of STR (|il)

0

2

4

6

8

10

4

The entire stable transfection of MDA-MB-231 with pEGFP-NlDNA procedure was
carried out under sterile conditions. The MDA-MB-231 cells were grown in RPMI1640/10% FCS in a 24-well plate until the cell culture reached 20-40% confluence
(about 48 hours) on the day of transfection. This was to ensure that the cells were at
the optimal phase of growth and in order to increase the efficiency of the expression
of the GFP gene.

An appropriate amount of purified pEGFP-Nl DNA (8 jig) was diluted with RPMI1640 (containing no serum and antibiotic) to a final volume of 150 |il. The sample
was mixed and aliquots containing 1 jig DNA were mixed with different volumes of
SuperFect Transfection Reagent as indicated in Table 2.1. The samples incubated at
room temperature (20-25°C) for 10 minutes, allowing the STR-DNA complexes to
form.

While the complex formation took place, each well of MDA-MB-231 cells was gently
washed once with 1 ml of sterile PBS. After the complex formation period, 1 ml of
RPMI-1640/10% FCS with 0.8 mg/ml active antibiotic Geneticin (purchased from
Life Technologies, Inc. Grand Island, NY, USA) was added into each reaction tube
containing the transfection STR-DNA complexes. The sample in each reaction tube
was mixed gently as before and immediately transferred to the different wells of
MDA-MB-231 cells in 24-well plate. The transfection complexes were incubated with
the cells for 3 hours in a humidified incubator at 37^C with a 5% carbon dioxide: 95%
air atmosphere. After the incubation period, the transfection solution was removed
from the cells by very gentle aspiration. Each well of cells was washed 4 times with 1
ml of sterile PBS. Finally 1 ml of fresh medium RPMI-1640/10%FCS was added into
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each well.
The transfected MDA-MB-231 cells were evaluated for GFP fluorescence after 48
hours and 72 hours under the fluorescence microscope. Cells that had successfully
integrated the pEGFP-Nl DNA into their chromosomes were routinely cultured in
RPMI-1640/10%FCS supplemented with final concentration 0.4 mg/ml active
Geneticin (G-418 Sulfate) as a selective agent. Only successfully transfected MDAMB-231 cells survived and divided.
After several weeks in culture, sufficient numbers of GFP expression MDA-MB-231
cells were obtained. The presence of GFP fluorescence in these cells was detected by
flow cytometry (Becton-Dickinson) using FL-1 detector (green fluorescent detector),
and photographed using a fluorescence microscope.
Highly GFP expressing MDA-MB-231+GFP cells were selected by fluorescence activated cell
sorting using flow cytometry (FACSort, Becton-Dickinson). Cells were cloned three times by

limiting dilution method. This involved placing 100 |il of cells (1x10^ /ml) into Al
well of the 96-well plate. A decade dilution down the first column of the plate was
performed, and followed by a decade dilution of this column of cells across the plate.
This dilution resulted in several wells containing 1 or no cells. The plate was
incubated until a single colony of GFP expression cells was observed under the
fluorescence microscope. Cells from this colony were used for subsequent serial
dilution. After third cloning step, cells were expanded and frozen down. The GFP
fluorescence of viable normal MDA-MB-231, before, and after sorting and cloning
MDA-MB-231+GFP cells was analyzed by dual colour flow cytometry (Becton-

Dickinson). All data were then analyzed by using CELLQuest software (BectonDickinson).

2.4 Characterization of breast cancer cell lines and prostate cancer cell line by
flow cytometry
In this study, the expression levels of cell surface uPA and endogenous PAI-2 of
viable MDA-MB-231 and HS-578-T, and MCF-7 cell lines were determined by
indirect immunofluorescence staining with FITC (a green fluorescent label). The
expression level of cell surface uPA of human prostate cancer cell line PCS was
determined by using the same technique.
All immunofluorescence labeling in these experiments was detected by dual-colour
flow cytometry (Becton-Dickinson, USA), using FITC and propidium iodide (PI)
fluorescence (as described in Ranson et al., 1998). The use of PI was to select only
viable cells for analysis. PI (an orange fluorescent label) intensity was measured using
the FL-2 detector of the flow cytometer. The viable FITC-labeled cells exclude PI and
dead cells can be 'gated out'. Only viable cells were selected for data analysis (Fig.
2.2). All data were analyzed using CELLQuest software (Becton-Dickinson).
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Figure 2.2 A diagrammatic representation of dual-colour flow cytometric
analyses used in this study. Dual-colour flow cytometry was used to detect
two different characteristics of the cells at the same time, using two different
fluorescent labels. The indirect or direct immunofluorescence labeling with
FITC (a green fluorescein) was used to determine the cell surface uPA and
PAI-2, while viable cells excluded dye propidium iodide (PI, an orange
fluorescent label). Only cells that excluded PI were selected as viable cells
for analysis. FITC fluorescence intensity was measured by FL-1 detector,
while, PI intensity was measured by FL-2 detector of flow cytometer.

Cells were firstly washed by PBS twice, then detached (after 48 hours of routinely
culturing) with PBS / 5nilVI EDTA, incubating at room temperature (20-25^C) for 3-4
minutes. Cells were washed and collected by centrifuging at 200g with ice-cold (4°C)
Hanks / 0.1% BSA (pH 7.5) at a final concentration of approximately 1x10^ cells / ml.
A sample of approximately 1x10^ cells was incubated with either mouse anti-human
uPA monoclonal antibody IgG #394 (American diagnostica Inc, Greenwich, CT,
USA, final concentration of 10 |ig/ml) or mouse anti-human PAI-2 (both 60 KDa and
46 KDa forms) monoclonal antibody IgG #3750 (American diagnostica Inc,
Greenwich, CT, USA, final concentration of 10 |Lig/ml) in 100 |il of ice cold Hanks /
0.1% BSA on ice for 30 minutes. In the case of isotype control, the same final
concentration of mouse anti-dinitrophenol IgG antibody DNP-P #399 (American
Diagnostica Inc, Greenwich, CT, USA) was added instead of the mouse anti-human
uPA or PAI-2 antibody. After incubation, cells were washed with 1 ml of ice cold
Hanks / 0.1% BSA twice then incubated with 1: 100 dilution of FITC conjugated antimouse IgG polyclonal antibody (Silenus, Sydney, NSW, Australia) in final 100 |il of
ice cold Hanks / 0.1% BSA for 30 minutes on ice and in the dark to prevent
photobleaching. Finally the cells were washed with Hanks / 0.1% BSA twice, and
resuspended in 500 [L\ of ice cold PBS/0.1% sodium azide containing 5 |ig/ml of
propidium iodide (PI). Immunofluorescence labeling was detected immediately by
dual colour flow cytometry using CELLQuest software (Becton-Dickinson).

In the case of transfected MDA-MB-231+GFP, PE (an orange fluorescent label)
conjugated anti-mouse IgG polyclonal antibodies (Silenus, Sydney, NSW, Australia)
was used because green fluorescence protein expression influenced the detectmg of

FITC fluorescence. PI could not used to select viable cells due to the fact that only
dual colour flow cytometry could be used successfully in this study.

Recombinant human PAI-2 (47 KDa) was obtained from Biotech Australia Pty Ltd.,
Sydney, Australia. PAI-2 was conjugated with FITC and TRITC as described by
Coding (1976). Unconjugated FITC or TRITC were separated by a PD-10 gel
filtration column equilibrated with PBS/0.1% azide. The concentration of FITC- or
TRITC conjugated PAI-2 was measured by Bio-Rad DC protein assay reagent kit
(Bio-Rad Pty Ltd. Australia) following the manufacturer's instruction. The binding
activities of FITC or TRITC conjugated PAI-2 were examined by their ability to form
complexes after 30 minutes incubation with equimolar amounts of active human uPA
(Serono, Sydney, NSW, Australia) at room temperature. The complex formation was
detected by SDS-PAGE (12% non-reducing gel, all reagents for SDS-PAGE from
Bio-Rad Pty Ltd. Australia). TRITC conjugated PAI-2 was used in the confocal
microscope experiments (refer to section 3.6).

Cells were harvested as above and resuspended in ice-cold (4°C) Hanks / 0.1% BSA
(pH 7.5) at 2x10^ cells / ml. Then samples of approximately 2x10^ cells were preincubated with or without plasminogen (20 |ig/ml) for 20 minutes at room
temperature as pre-activated or non-activated groups. After washing with ice-cold
Hanks / 0.1% BSA twice, the cells were incubated with FITC-PAI-2 for varying time
(from 0 to 16 hours) at a final concentration of 10 \ig/m on ice in the dark. The cells
were washed, and cell surface binding PAI-2 was detected by dual colour flow
cytometry. In some cases cells were fixed after pre-activation with plasminogen in 1%
paraformadenyde / PBS over 1 hour at room temperature, prior to FITC-PAI-2

binding experiments as indicated. All data were analyzed by using CELLQuest
software (Becton-Dickinson).

2.5 Examination of exogenous PAI-2 binding and internalization in MDA-MB231+GFP cells by confocal microscopy

Before final sorting and cloning, MDA-MB-231+GFP cells were used in a
preliminary experiment to determine exogenous PAI-2 binding and internalization
capacities using confocal microscopy (Leica DM IRB, with Leica TCS confocal
system (Fig. 2.3).
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Figure 2.3 A model of Leica DM IRB confocal microscope with Leica TCS
confocal system (Leica Microsystems, Wetzlar Gmbh).

Confocal microscopy detects structures by collecting light from a single focal plane of
the sample, excluding light that is out of focus. In a point scanning confocal system,
the microscope lenses focus the laser light on one point in the specimen at a time (the
focal point). The laser moves rapidly from point to point to produce the scanned
image. Both fluorescent and reflected light from the sample pass back through the
objective. The microscope and the optics of the scanner module focus the fluorescent
light emitted from the focal point to a second point, called the confocal point. The
pinhole aperture, located at the confocal point, allows light from the focal point to
pass through the detector. Light emitted from outside the focal point is rejected by the
aperture (Fig.2.4).
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Figure 2.4 The epi-illumination imaging mode
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Cells were cultured on the top of round glass slide covers in a 24-well plate with
RPMI-1640/10%FCS medium until they reached 40%-60% confluence (about 48
hours). The cells in each well were very gently washed with 1 ml of Hanks /1% BSA
twice, and pre-incubated with or without 20 |xg/ml plasminogen for 20 minutes at
room temperature as pre- or non-plasminogen activated cell samples. Then samples of
approximately 2x10^ cells were incubated with 200 |il Hanks / 1% BSA containing a
final concentration 10 |ig/ml TRITC-PAI-2 in the dark. The fluorescence present the
on cell surface or in the cytosol was detected by confocal microscopy at different time
points. All data were analysed by Leica TCS software in Leica TCS confocal system.
2.6 Human breast cancer in vivo nude mice model
In this study, 4 and 6-week-old female Arc(s) nu/nu nude mice were purchased from
Animal resources Center, Canning Vale, WA, Australia. Throughout all experiments,
mice were maintained in a laminar flow cabinet under specific-pathogen-free
conditions and monitored regularly in accordance with the Animal Ethics Conmiittee
of the University of Wollongong (AE 96/07).
Human breast cancer cells MDA-MB-231 and MDA-MB-231+GFP were routinely
cultured in sterile RPMI-1640/10%FCS medium and tested free from mycoplasma
contamination by PCR technology at Department of Microbiology, Westmead
Hospital (Sydney) before xenografting. Under sterile conditions, cells were harvested
with sterile PBS/EDTA, washed and resuspended with serum-free RPMI-1640
medium at a final concentration of 2x10^ cells/ml. Xenografts of human breast cancer
cells were induced by subcutaneous inoculation of 2 x lO^cells into the first pair of

mammary fat pads on the 4- or 6-week-old nude mice thoracic wall. The mice were
sacrificed when the tumours were bigger than 1.0 cm in diameters or at 8 weeks from
the initial inoculation. The samples of tumour and major organs were stored in 10%
formalin solution for future histopathological assays. Dissecting images of mice,
tumours, tumour angiogenesis phenomenon and metastatic lymph nodes were
captured by video camera and analysed using a Power PC (Macintosh 8500/20)
computer with Apple Video Player software (Macintosh).

3. RESULTS
3.1 Determination of pEGFP-Nl DNA purification yield
The pEGFP-Nl DNA was successfully extracted and purified from DH5a bacteria
using Qiagen Plasmid Midi kit as determined by BLUE spectrophotometry (range of
A260nm/A280nm' 1.8-2.0). The extracted pEGFP-Nl was an uncut supercoiled form (3.5
Kb in size). Digestion of a sample of this original pEGFP-Nl with restriction
endonuclease Bgl 11 is predict to produce a linearised pEGFP-Nl (4.7 Kb in size).
Bands of 3.5 Kb and 4.7 Kb which corresponded to the exact size of supercoiled and
linearised pEGFP-Nl respectively were observed, confirming that the extracted DNA
was that of pEGFP-Nl (Fig. 3.1).

Restriction linearised pEGFP-Nl (4.7 Kb)
Uncut supercoiled pEGFP-Nl (3.5
Kb)

Figure 3.1 Electrophoresis result of uncut and restriction pEGFP-Nl
examining. Lane 1 contained the 1 Kb ladder DNA marker. Lane 2 contamed
a sample of uncut pEGFP-Nl. Lane 3 contained a sample of pEGFP-Nl
digested with Bgl 11.

3.2 Stable transfection of adherent MDA-MB-231 cells with pEGFP-Nl plasmids

The best result of stable transfection with pEGFP-Nl was obtained with the ratio of 4
|ll SuperFect Transfection Reagent to 1 |ig pEGFP-Nl DNA. Transfected cells
obtained using the other ratios gradually died after culturing with Geneticin (0.4
mg/ml).

After cell sorting by flow cytometry, only the highest GFP expressing cells were
selected by incubation with the antibiotic Geneticin as described above. Cloning of a
single cell was attempted. Then a single colony originating from one single highest
GFP expression cell was selected and cultured. A new clone MDA-MB-231+GFP,
which had heterogeneous GFP expression due to either incomplete cloning or variable
expression at different stages of cell cycle, was obtained and maintained. Without
further Geneticin selection, this clone stably kept high GFP expression for at least 13
passages. The MDA-MB-231+GFP cells were photographed at the

passage under

the fluorescence microscope (Fig. 3.2). The MDA-MB-23H-GFP cells were
compared with untransfected or unsorted but transfected MDA-MB-231 cells by dualcolour flow cytometry (Fig. 3.3 and 3.4).

Figure 3.2 shows that almost all MDA-MB-231+GFP cells seen under the normal
light source expressed green fluorescence under blue light stimulation, which
confirmed the positive results of GFP gene transfection in this study. The cells marked
with GFP were easily and clearly detected under blue light source microscopy.

Figure 3.3 shows the density plots of FITC intensity vs PI intensity of (A) the

untransfected normal MDA-MB-231 cells, (B) the mixed population of transfected
MDA-MB-231 cells with low or high different GFP expression prior to cell sorting
and cloning, and (C) the population of MDA-MB-231+GFP cells. The viability of the
cells was assessed by the PI intensity. Non-viable cells were more permeable and able
to uptake PI giving a bright orange fluorescence, whereas, viable cells were not
permeable and were able to exclude PL The viable cells were gated in density plots
and analyzed for FITC intensity in histogram plots (Figure 3.3 and 3.4). As shown in
Figure 3.4 untransfected normal MDA-MB-231 cells had a very low level of FITC
intensity that indicated these cells have a very low FITC-autofluorescence activity
(2.3 ± 0.2 fluorescence units, n=3) and no GFP expression. Before cell sorting and
cloning, there were two populations of transfected cells with very different levels of
FITC intensity, which indicated one part of these transfected cells had a high GFP
expression (1180 ± 40 fluorescence units, n=3), while another one had a low GFP
expression (4.7 ± 0.4 fluorescence units, n=3). After cell sorting and cloning, one
population of high GFP expression cells (MDA-MB-231-GFP) was found (1210 ± 60
fluorescence units, n=3). This population of cells maintained high GFP expression
after 13'^ passages in the absence of Geneticin, indicating that the GFP gene was
stably maintained on the genome of these cells. This new cell line MDA-MB231+GFP could therefore be used in the future for in vivo experiments as an easily
monitored human breast cancer cell line.
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Figure 3.2 Stably transfected MDA-MB-231+GFP cells under normal
light and blue light source of fluorescence microscope. A) cells under
normal light source (x 100 times). B) same cells as A under blue light
source (x 600 times). C) cells under normal light source (x 100 times). D)
same cells as C under U. V. light source (x 600 times). The MDA-MB231-GFP cells have heterogeneous GFP expression due to different stages
of cell cycle.
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Figure 3.3 Density plots showing green fluorescent protein (GFP) expression of
MDA (normal MDA-MB-231) cells and MDA+GFP (stable transfected MDA-MB231+GFP) cells. All cell samples were resuspended in buffer with 5 |ig/ml PI for
analyzing by dual-colour flow cytometry. The FITC intensity represented the relative
level of cytosolic GFP expression by cells, whereas, PI intensity represented the viability
status of cells. A) Normal MDA-MB-231 (MDA) cells only. B) A mixed population of
low (Low-GFP-MDA) and high (High-GFP-MDA) GFP expressing MDA-MB-231
cells before cell sorting and cloning; High-MDA-GFP cells were then gated and sorted
by FACSort. C) A population of high GFP expressing MDA-MB-231+GFP
(MDA+GFP) cells after cell sorting and cloning.
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Figure 3.4 Histogram plots showing GFP expression. The FITC intensity was due
to the cell GFP expression. A) Overlay of gated density plots shown in Figure 3.3
A+B, comparing fluorescence associated with untransfected (MDA) and transfected
MDA-MB-231 cells prior to sorting and cloning (Low-GFP-MDA & High-GFPMDA). B) Overlay of density plots shown in Figure 3.3 A+C, comparing
fluorescence associated with the untransfected MDA-MB-231 (MDA) and the sorted
and cloned high GFP expression MDA-MB-231+GFP (MDA+GFP) cells.

3.3 Levels of cell surface uPA expression of breast and prostate cancer cell lines

3.3.1 MDA-MB-231, HS-578-T and PC3 cell lines

High level of cell surface uPA and uPAR expression on the human breast cancer cell
lines MDA-MB-231 (Ranson et a l , 1998), HS-578-T (Ranson, unpubUshed) and low
levels of cell surface uPA and uPAR expression on MCF-7 (Ranson et al, 1998) have
been shown by flow cytometry.

In this study, the characteristic high levels of cell surface uPA expression on
metastatic human breast cancer cell lines MDA-MB-231 and HS-578-T and low level
of that on non-metastatic cell line MCF-7 were confirmed by dual colour flow
cytometry. The viable cells were assayed by indirect immunofluorescence labeling of
cell surface uPA antigen with FITC and detected by dual colour flow cytometry. The
cell surface uPA expression on metastatic human prostate cancer cell line PC3 was
also determined. These results are shown in the density plots of FITC intensity vs PI
intensity (Fig. 3.5) and histogram plots of viable cells only (Fig. 3.6).

As shown in Figure 3.6, all populations of viable cells in the autofluorescence and
isotype control have a very low level of FITC intensity which indicated that all four
cell lines have a low level of FITC-autofluorescence activity and non-specific cell
surface binding for mouse IgG. As a consequence, this finding implicated that most of
the FITC intensity observed in the assays would be due to specific labeling of cell
surface uPA. High levels of FITC intensity were observed in the populations of viable
HS-578-T, MDA-MB-231 and PC3 cells of the uPA detecting samples (160 ± 10

M

fluorescence units for HS-578-T, 86 ± 7 fluorescence units for MDA-MB-231, and 57
± 3 fluorescence units for PCS, n=3), indicating that these three cell lines express high
levels of cell surface uPA. Low levels of FITC intensity were found the MCF-7 cell
line (3 ± 1 fluorescence units, n=3), indicating the MCF-7 cell line had low levels of
cell surface uPA expression.
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Figure 3.5 Density plots showing uPA expression of (A) HS-STS-T, (B M D A - ^ ^ 3 1 , C) MCF-7
and (D) PC3 cells. Cells were incubated with mouse anti-human uPA antibody #394 dO ^ig/m ),
washld then incubated with FITC labeled secondary antibody, washed agam
buffer with PI (5 ng/ml). Cells that excluded PI (i.e. low PI intensity) were gated as Viable cells. (A ),
(B'), ( C ) and (D') are negative controls for each cell hnes.
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Figure 3.6 Histogram plots showing cell surface uPA expression of viable (A)
HS-578-T, (B) MDA-MB-231, (C) MCF-7 AND (D) PC3 cells. The histograms
were constructed from gated viable cells shown in Figure 3.5. Auto, autofluorescence level of untreated cells. Isotype, mouse anti DNP-P #399 antibody (10
|Lig/ml). uPA, mouse anti-human uPA antibody #394 (10 jxg/ml).

3.3.2 MDA-MB-231+GFP cells

In the case of transfected MDA-MB-231+GFP cells, the expression level of cell
surface uPA was compared with that of normal MDA-MB-231 cells by indirect
immunofluorescence staining with PE due to the influence of inherent green
fluorescence protein. MDA-MB-231 and MDA-MB-231+GFP cells were mixed
together as samples for the assay. The results are shown in the Figure 3.7 and 3.8.

Figure 3.7 shows the density plot of FITC intensity vs PE intensity of the (A)
autofluorescence, (B) uPA-binding and (C) non-specific binding (isotype control) of
mixed MDA-MB-231 and MDA-MB-231-hGFP cells. The density plots shows that
each sample contained two distinctive populations of low (2.6 ± 1 fluorescence units,
n=3) and high (1280 ± 60 fluorescence units, n=3) FITC intensity cells, which reflect
the MDA-MB-231 and MDA-MB-231+GFP cells, respectively. Similar high levels of
PE intensity associated with cell surface uPA antigen were observed in both
populations of cells, compared with low PE intensity levels of auto fluorescence and
isotype samples in separated histogram plots (Fig. 3.8), indicating that transfected
MDA-MB-231+GFP cells (44 ± 6 PE fluorescence units, n=3) retain the same high
expression level of cell surface uPA as the MDA-MB-231 cells (47 ± 5 PE
fluorescence units, n=3).
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Figure 3.7 Density plots showing uPA expression on MDA-MB-231 (MDA) and
MDA-MB-231+GFP (MDA+GFP) cells. The FITC intensity represented the relative
levels of GFP expression, whereas, PE intensity represented the relative levels of uPA
expression. A) Auto, auto-fluorescence level. B) uPA, mouse anti-human uPA
antibody #394 (10 |ig/ml). C) Isotype, mouse anti DNP-P antibody #399 (10 ^tg/ml).
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Figure 3.8 Histogram plots showing uPA expression on MDA-MB231 (MDA) and MDA-MB-231+GFP (MDA+GFP) cells. The
histogram plots were constructed from density plots shown in Figure
3.7. A) Overlay of density plots of MDA cells shown in Figure 3.7
A+B+C. B) Overlay of density plots of MDA+GFP cells shown in
Figure 3.7 A+B+C. Auto, auto-fluorescence level. Isotype, mouse anti
DNP-P antibody #399. uPA, mouse anti-human uPA antibody #394.
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3.4 Levels of cell surface endogenous PAI-2 of breast cancer cell lines
Due to the time limitation, this study concentrated on the PAI-2 properties of breast
cancer cell lines. The levels of cell surface endogenous PAI-2 of viable MDA-MB231, HS-578-T and MCF-7 cells were determined by indirect immunofluorescence
labeling of cell surface PAI-2 antigen with FITC and detected by dual colour flow
cytometry. Dual colour flow cytometric analyses of endogenous PAI-2 expression on
three cell lines, HS-578-T (A), MDA-MB-231 (B) and MCF-7 (C), are shown in the
density plots of FITC intensity vs PI intensity (Fig. 3.9) and histogram plots of viable
cells (Fig. 3.10). In all viable cells expression of endogenous PAI-2 was low
(fluorescence units after minus isotype control for viable HS-578-T, MDA-MB-231
and MCF-7 cells are 5.11 ± 0.14, 3.97 ± 0.15 and 0.02 ± 0.01, respectively). A small
difference between metastatic cells HS-578-T, MDA-MB-231 and non-metastatic
cells MCF-7 was noted. The higher level of endogenous PAI-2 in non-viable cells
may reflect the presence of cytosolic form of PAI-2 (Darren Saunders personal
communication).
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Figure 3.9 Density plots showing endogenous PAI-2 expression on (A) HS-578-T, (B) MDA-MB-2:

(C) MCF-7 cells. (A'), (B') and (C) are negative controls for each cell lines. Cell were incubated with
anti-human PAI-2 antibody (mAb #3750, 1:50 dilution) or same concentration isotype mouse antiantibody (#399), washed, the incubated with a FITC labelled secondary antibody (1:100 dilution),
again, and resuspended in buffer with PI (5 |Lig/ml) and analysed by dual-colour flow cytometry. Ce
excluded PI (i.e. low PI intensity) were gated as viable cells, whereas, cells that uptake PI (i.e. 1
intensity) as non-viable cells.
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Figure 3.10 Histogram plots of cell surface endogenous PAI-2 on (A) HS-578-T,

(B) MDA-MB-231 and (C) MCF-7 cells. The histogram plots were constructed
from gated viable cells shown in Figure 3.9. Auto, auto-fluorescence level.
Isotype, mouse anti DNP-P antibody (10 |Xg/nil). PAI-2, mouse anti-human PAI-2
antibody #3750 (10 |ig/ml).

3.5 Levels of cell surface exogenous PAI-2 binding of MDA-MB-231 and HS-578T metastatic breast cancer cell lines.
Another important aspect of this study was to determine whether exogenous PAI-2
could specifically bind to the high level of cell surface bound uPA on metastatic
cancer cells and be internalized into the cells. The levels of cell surface exogenous
PAI-2 binding of viable metastatic MDA-MB-231 and HS-578-T cells were assayed
by direct labeling with FITC-conjugated PAI-2 and detected by dual colour flow
cytometry. On the low cell surface uPA expressing, non-metastatic MCF-7 cell line
exogenous cell surface PAI-2 binding was not detectable (data not shown).

3.5.1 PAI-2 Conjugation
The uPA binding activities of FITC or TRITC conjugated PAI-2 were examined by
their ability to form uPA:FITC/TRITC-PAI-2 complexes by SDS-PAGE. A 1:1 molar
ratio of uPA and PAI-2 or FITC/TRITC conjugated PAI-2 were pre-incubated at 37°C
for 30 minutes before running the gel. The results for FITC-PAI-2 are shown in the
Figure 3.11. Lane 4 contains unconjugated PAI-2 monomer at 47 Kda and a PAI-2
dimer contaminant at 97 Kda. Similar size bands indicative of complexes at
approximately 80 and 90 Kda were found using unconjugated PAI-2 or conjugated
PAI-2. The 97 Kda band found in lane 5 which contains uPA and unconjugated PAI-2
correspond to the PAI-2 dimer contaminant found in lane 4. The uPA-FITC-PAI-2
complexes and free FITC-PAI-2 were detected under blue light in the same gel, while
other bands were undetectable. Similar results were obtained with TRITC conjugated
PAI-2 (data not shown). The concentration of FITC/TRITC conjugated PAI-2 was
measured by Bio-Rad DC protein assay reagent kit following the manufacture

instruction. The final concentrations of FITC or TRITC conjugated PAI-2 used in the
assays were both diluted to Img/ml.

97KD

uPA (55KDa):FITC-PAI-2
UFA (35KDa):FITC-PAI-2

66KDa_^
PAI-2/FITC-PAI-2 (47KDa)
45KDa—•
B
uPA:FITC-PAI-2
FITC-PAI-2

Figure 3.11 FITC conjugated PAI-2 forms a SDS-stable complex with uPA as
well as unconjugated PAI-2. Lane 1 and 2 contained the bands of Bio-Rad's Low
and High MW SDS-PAGE Standards. Lane 3 contained a sample of uPA. Lane 4
contained a sample of PAI-2. Lane 5 contained a sample of 1:1 molar ratio of uPA and
PAI-2. Lane 6 contained a sample of 1:1 ratio of uPA and FITC-PAI-2. (A) gel picture
under normal light source. (B) gel picture under blue light source.

3.5.2 Levels of cell surface exogenous FITC-PAI-2 binding

A time course was firstly carried out to monitor the cell surface exogenous PAI-2
binding levels of MDA-MB-231 cells. The viable cells were assayed by direct
inmiunofluorescence labeling with FITC-PAI-2. Therefore, the intensity of FITC
reflected the level of exogenous PAI-2 binding on cell surface of MDA-MB-231 cells.
With and without pre-plasminogen activation cells were separately assayed by dual
colour flow cytometry after 0 hour, 1 hour, 2 hours, 4 hours, 6 hours and overnight.
Results of viable pre- or non-plasminogen activation cells in different time points
were compared in the Figure 3.13.

FITC
Intensity

Incubation Time (hours)
Figure 3.12 Cell surface FITC-PAI-2 binding time course of viable
MDA-MB-231 cells. +plg, pre-plasminogen activated cells (20
^g/ml, 20 minutes, R.T). -pig, non-plasminogen activated cells.
Subsequently cells were incubated with 10 |ig/ml FITC-PAI-2 on ice
in the dark. The maximum FITC intensity was observed at 2-hour
incubation time point.

Although only a small difference found between pre-plasminogen activated and nonactivated cells in the time course assay (Fig. 3.12), all cells were pre-activated by 20
|lg/ml plasminogen to stimulate the specific FITC-PAI-2 binding with cell surface
bound uPA. Non-specific binding with FITC-BSA was used as control. The specific
binding of FITC-PAI-2 to uPA was also determined by comparing the cells preincubated with uPA specific inhibitor, i.e. 0.5 mM Glu-Gly-Arg-chloromethylketone
(EGR-CMK). The viability of the cells was assessed by the PI intensity as described
in section 3.2. Only viable cells were selected for comparison in histogram plots of
FITC intensity (Fig. 3.13).
As shown in Figure 3.13, all populations of viable cells in the autofluorescence and
BSA control samples have a low level of FITC-autofluorescence activity (between
1.85 and 4.37 fluorescence units) and non-specific cell surface binding for FITC-BSA
(between 2.12 and 2.63 fluorescence units). A small increase of FITC intensity was
found in viable MDA-MB-231 and HS-578-T (19.3 ± 2.1 and 18.2 ± 2.2 fluorescence
units, respectively, n=3) cells surface. Much higher levels of FITC intensity were
observed in fixed MDA-MB-231 and HS-578-T (86.2 ± 5.2 and 81.1 ± 5.2
fluorescence units, respectively, n=3, data not shown) cells, this may due to the
cytosolic form of PAI-2. Furthermore, a decrease of FITC intensity levels was found
in viable cells treated with uPA specific inhibitor EGR-CMK, while compared with
non-EGR-CMK pre-treated samples (difference of fluorescence units were 8.7 ± 0.3,
and 9.9 ± 0.1 for viable MDA-MB-231 and HS-578-T, respectively).
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Figure 3.13 Histogram plots of cell surface exogenous FITC-PAI-2 binding of (A)
viable MDA-MB-231, (B) viable HS-578-T cells. The FITC intensity was due to the
direct labeling with FITC conjugated PAI-2 (FITC-PAI-2). Cells were pre-activated
by 20 lig/ml plasminogen to active cell surface uPA, then pre- or non-incubated with
0.5 mM uPA specific inhibitor EGR-CMK (30 min at RT). Finally cells were
incubated with 10 |xg/nil FITC-PAI-2 or 10 iig/ml FITC-BSA for 2 hours on ice. Cells
then were washed, resuspended in buffer with 5 }ig/ml PI, and analyzed by dual colour
flow cytometry. Auto, auto-fluorescence level; Isotype, FITC-BSA; EGR, EGRCMK.

3.6 Preliminary confocal microscopy to examine exogenous PAI-2 binding and
internalization by MDA-MB-231+GFP cells
Flow cytometry showed that exogenous PAI-2 bound specifically to the cell surface
bound uPA as described in section 3.5. Confocal microscopy techniques allowed
exogenous TRITC-PAI-2 binding capacity to be visualized on MDA-MB-231+GFP
cells that were attached and spread onto substrata. Similar results were obtained with
MDA-MB-231 cells (data not shown). Images were captured on Leica TCS software
(Figure 3.14). Lower levels of TRITC-PAI-2 binding were found in non-plasminogen
activated cells (Fig 3.14 A & B), compared to the higher levels found in plasminogen
activated cells (Fig 3.14 C & D). With time TRITC-PAI-2 binding increased in the
plasminogen activated cells; compare 5-minute TRITC-PAI-2 incubation (Fig 3.14 C)
with 15-minute TRrrC-PAI-2 incubation (Fig 3.14 D). Possible internalization of
TRrrC-PAI-2 (dots indicated by arrows) was only observed in the Figure 3.14 D. This
effect was first observed at 10 minutes (data not shown). These results visually
confirmed exogenous PAI-2 was binding to cells presumably via cell surface uPA. In
order to confirm internalization of TRITC-PAI-2, multiple optical sections will need
to be performed in future experiments. More experiments using confocal microscopy
in other cell lines will help us to understand more about PAI-2 and its role in the
plasminogen activation system of cancer cells.
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Figure 3.14 Confocal microscopy showing exogenous TRITC-PAI-2 internalization by
MDA-MB-231+GFP ceils. GFP, MDA-MB-231-KJFP cells. TRITC, TRITC-PAI-2
(lO^g/ml). Overiay, TRITC-PAI-2 internalization by MDA-MB-231+GFP cells. (A) and
(B), TRITC-PAJ-2 incubation with non-plasminogen activated cells at 5 and 15 minutes.
(C) and (D), TRITC-PAI-2 incubation with pre-plasminogen activated cells (20fig/ml, for
20 minutes at R.T) at 5 and 15 minutes.
in (D) indicated positive images of TRITCPAI-2 internalization by pre-plasmmogen activated MDA-MB-231+GFP cells.

3.7 Human breast cancer in vivo nude mice model

Xenografts of human breast cancer were induced by subcutaneous inoculation of
2x10^ MDA-MB-231 or MDA-MB-231+GFP cells into the first pair of mammary fat
pads of 4-week-old nude mice (10 mice for MDA-MB-231 cells, 5 mice for MDAMB-2314-GFP cells). Visible tumours

3 mm x 3 mm in dimensions) were observed

in 27/30 inoculated sites in nude mice after 2 weeks (Fig. 3.15). The growth of
tumours accelerated when they reached 5 mm x 5 mm in dimensions (around 3-4
weeks after cell inoculation). The rates of tumour growing were different in individual
mice, but most tumours reached 10 mm x 10 mm in dimensions before 8 weeks after
cell inoculation (Fig. 3.16). The phenomenon of angiogenesis around tumour and
tumour invaded skin were observed in nude mice sacrificed at 4 weeks after cell
inoculation (Fig 3.17 and 3.18). No visible metastases were observed in major organs
(lung, liver, spleen, kidney etc.). The abnormal lymph nodes, which are bigger and
harder than normal lymph nodes, were observed in two sides auxiliary and cervical
spaces of nude mice. The samples of xenografted tumours, lymph nodes and major
organs were stored in 10% formalin solution. The preliminary histopathological
assays confirmed the presence of cancer cells in breast tissues, auxiliary and cervical
lymph nodes of nude mice (performed by Department of Pathology, St. George
Hospital, Kogarah). Furthermore, the primary tumour and metastatic cancer cells in
lymph nodes stained positively for uPA antigen (Fig 3.19) (performed by Dr JL Yang,
Prince of Wales Hospital, Randwick). Interestingly, two sides of lymph nodes which
invaded by cancer cells were observed even in the mice that only had one side of
xenografted tumour (Fig 3.20), which is very similar to distant lymphatic metastases
of clinical breast cancer patients. The primary tumours induced by MDA-MB-
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Figure 3.15 A visible xenografted breast tumour of a nude mouse. (A) the
normal breast of a nude mouse; (B) the xenografted breast tumour of a nude
mouse, 2 weeks after cells inoculation.

Figure 3.16 Pictures showing xenografted breast tumours in
nude mice. (A) 6 weeks after inoculation of MDA-MB-231 cells
(B) 6 weeks after inoculation of MDA-MB-231+GFP cells.
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Figure 3.17 Pictures showing angiogenesis in the tumour invaded skin of
a nude mouse. This mouse, which only had tumour on left side, was
sacrificed at 4 weeks after cell inoculation. (A) the right side external image
of the normal skin. (B) the left side external image of the tumour invaded
skin. (C) the right side internal image of the normal skin. (D) the left side
internal image of the tumour invaded skin.

Figure 3.18 Pictures showing angiogenesis (Qi) around the primary
xenografted breast tumour in a nude mouse. (A) x 6.4 times; (B) x 10 times.
The mouse was sacrificed at 4 weeks after cells inoculation.
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Figure 3.19 Histopathological sections showing cancer cells in xenografted primary
breast tumours and metastatic lymph nodes of nude mice. Paraffin sections were
stained with uPA mAb #394 (brown) to identify the uPA antigen positive cancer cells.
(A) primary tumour (HE stain, x 100 times). (B) primary tumour (uPA mAb
immunohistochemistry staining, x 400 times). (C) metastatic lymph node (uPA mAb
immunohistochemistry staining, x 100 times). (D) metastatic lymph node
(immunohistochemistry staining, x 200 times).
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Figure 3.20 External and correspondence internal view of a nude mouse 4
weeks post MDA-MB-231 cells inoculated into the mammary fat pad on LHS
only. Internal view shows presence of enlarged lymph nodes suggesting bilateral
metastases from the primary tumour. RHS, right hand side. LHS, left hand side.
LN, lymph node.

4. DISCUSSION

The overall aim of this project was to assess the viability of using PAI-2 as a device to
target a marker of malignant cancer cells i.e. cell bound uPA. This was addressed in
four major experimental parts: stable transfection, dual colour flow cytometry,
confocal microscopy and breast cancer animal models. Results of this project built up
a strong base for further human targeted anti-cancer therapy projects.

The green fluorescent protein (GFP) gene was successfully transfected into MDAMB-231 cells. A new, stable transfected cell line MDA-MB-231+GFP was produced
after cell sorting and cloning. Compared with MDA-MB-231 cells, a one thousand
fold increase in green fluorescence intensity was detected in MDA-MB-231+GFP
cells by flow cytometry. In addition, the GFP expression in these cells was stable even
in the absence of Geneticin. This suggested that this cell line would not lose its
capacity to produce GFP when inoculated into mice as a xenograft. Thus the use of
MDA-MB-231+GFP xenografts may present a good model to follow the metastasis of
cancer cells, which is similar to the model described in Farina et al. (1998).

Dual colour flow cytometry was extensively used in this project to determine uPA,
endogenous PAI-2 expression and exogenous FITC-PAI-2 binding on the cell
surfaces. The high levels of cell surface uPA expression on metastatic breast cancer
cell lines MDA-MB-231and HS-578-T compared to low level expression on the nonmetastatic cell line MCF-7 were confirmed. Similarly high levels of uPA expression
between MDA-MB-231 and MDA-MB-231+GFP cells indicated that the transfected
cells maintained this important characteristic of metastatic breast cancer cells. The
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high level of cell surface uPA expression was also observed on the metastatic prostate
cancer cell line PC3, confirming an association between over-expression of uPA and
cancer cell metastatic capacity.

The level of cell surface endogenous PAI-2 was low in all viable breast cancer cells.
A small difference was found between metastatic (higher endogenous PAI-2) and nonmetastatic (lower endogenous PAI-2) breast cancer cells, agreeing with Western
blotting observations (Darren Saunders personal communication, data not shown).
The higher level of endogenous PAI-2 in non-viable cells was noted. This reflects the
presence of cytosolic form of PAI-2, the function of which is still uncertain (Darren
Saunders personal communication). Specific binding of exogenous FITC-PAI-2 to
MDA-MB-231 and HS-578-T cell surface confirmed the observation that PAI-2
specifically binds to cell surface uPA by Hang et al. (1998).

The mechanism of PAI-1 internalization into cells via specific uPA binding on cell
surface has been reported (Cubellis et al., 1990; Conesi and Blashi, 1995). The
internalization of PAI-2 may be by a similar mechanism. The confocal microscopy
results visually observed the possible internalization of PAI-2 by MDA-MB-231+GFP
cells and indicated internalization of PAI-2 most likely via specific uPA binding. Thus
the use of PAI-2 as a device to target uPA over-expressing malignant cancer cells and
carry the lethal medicament into these cells is promising.

Once the ideal targeting marker of malignant cancer cells and targeting device to carry
the medicament has been established, the challenge of building up an effective human
cancer metastasis animal model remains in the development of targeted anti-cancer

therapy. Human breast cancer tumours xenografts were successfully induced in nude
mice using MDA-MB-231 and MDA-MB-231+GFP cells. Cancer cells were
identified histologically in sections taken through primary xenografted tumours tissue
and in nearby lymph nodes (i.e.tumour side axillary lymph nodes) and distant lymph
nodes (i.e. tumour side cervical and no-tumour side axillary and cervical lymph
nodes). Furthermore, the positive uPA antigen expression on primary and metastatic
cancer cells were identified immunohistochemically.

This lymphatic metastatic model of human breast cancer in nude mice is very similar
to the human breast cancer metastasis process, which is primarily through the
extensive lymphatic drainage around the breast (Iglehart, 1997). In results of a 5-year
national survey by the American College of Surgeons (Nemoto et al., 1980), the
overall survival rate of female breast cancer patients with and without metastatic
lymph nodes was 50.9% and 71.8%, respectively, showing the important association
between lymphatic metastasis and patient survival in breast cancer. Further studies
using PAI-2-medicament complexes to target and kill metastatic cancer cells in lymph
nodes may be carried out in this useful animal model, and by using GFP expression
cancer cells to identify the therapy effects.

The other important factors in developing targeted therapy include the choices of
lethal medicament and conjugating reagents to link PAI-2 or other carriers and
medicament. In the history of targeted anti-cancer therapy, the medicament used to
conjugate with antibody includes immunotoxins (e.g. ricin, pseudomonas exotoxin,
diphtheria toxin and their derivatives etc.), anti-cancer drugs (include antimetabolites,
alkylating

agents and intercalating drugs etc.), and traditional

beta-emitting

radioisotopes (Goldenberg, 1993). Although they have produced some improvement,
the control of metastatic diseases has not been achieved. To achieve the ideal object of
controlling metastatic cancer growth, we need to find some medicament that has the
ability to kill all targeted cancer cells effectively at tolerable dose limits (i.e. sparing
stem cells in marrow while killing metastatic cancer cells), such as short-range
radioisotopes.

In conclusion, results of this project explored the promising value of the human
recombinant PAI-2 and MDA-MB-231-i-GFP cell line in further targeted anti-cancer
therapy projects (especially in breast cancer).
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